<SEC-DOCUMENT>0001193125-12-112058.txt : 20120313
<SEC-HEADER>0001193125-12-112058.hdr.sgml : 20120313
<ACCEPTANCE-DATETIME>20120313161700
ACCESSION NUMBER:		0001193125-12-112058
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20120313
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20120313
DATE AS OF CHANGE:		20120313

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			STEMCELLS INC
		CENTRAL INDEX KEY:			0000883975
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				943078125
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19871
		FILM NUMBER:		12687326

	BUSINESS ADDRESS:	
		STREET 1:		3155 PORTER DRIVE
		STREET 2:		.
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94304
		BUSINESS PHONE:		6504753100

	MAIL ADDRESS:	
		STREET 1:		3155 PORTER DRIVE
		STREET 2:		.
		CITY:			PALO ALTO
		STATE:			CA
		ZIP:			94304

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CYTOTHERAPEUTICS INC/DE
		DATE OF NAME CHANGE:	19930328
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d314798d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>FORM 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>WASHINGTON, D.C. 20549 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K
</B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) of the </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Securities Exchange Act of
1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of Earliest Event Reported): March&nbsp;13, 2012 </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>StemCells, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact name of registrant as specified in its charter) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>000-19871</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>94-3078125</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or other jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>of incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>File Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(I.R.S. Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>7707 Gateway Blvd, Suite 140, Newark,</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>California</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>94560</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of principal executive offices)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Zip Code)</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Registrant&#146;s telephone number, including area code: 510.456.4000 </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Not Applicable </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Former name or former address, if changed since last report </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;2.02 Results of Operations and Financial Condition. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On March&nbsp;13, 2012, StemCells, Inc. (the &#147;Company&#148;) issued a press release announcing its financial results for the three months and year
ended December&nbsp;31, 2011. A copy of this press release is attached hereto as Exhibit 99.1. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company will host a live conference call
and webcast on March&nbsp;13, 2012, at 4:30 PM Eastern Time (1:30 PM Pacific Time), to discuss its financial results and recent business activities. Interested parties are invited to listen to the call over the Internet via the Investors section of
the Company&#146;s website at http://investor.stemcellsinc.com/phoenix.zhtml?c=86230&amp;p=irol-irhome. An archived version of the webcast will be available for replay on the Company&#146;s website beginning approximately two hours following the
conclusion of the live call and continuing for a period of 30 days. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The information set forth in Items 2.02 and 9.01 of this current report
Form 8-K, including the attached exhibit, is being furnished to the SEC and shall not be deemed &#147;filed&#148; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (&#147;Exchange Act&#148;), or otherwise subject to
the liabilities of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation
language in such filing. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01 Financial Statements and Exhibits. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(d) Exhibits </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exhibit 99.1 Press Release, dated March&nbsp;13, 2012, announcing the
Company&#146;s financial results for the three months and year ended December&nbsp;31, 2011. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="54%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="39%"></TD></TR>


<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">StemCells, Inc.</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>March&nbsp;13, 2012 </I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>By:</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>/s/ Kenneth Stratton </I></FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Name: Kenneth Stratton</I></FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Title: General Counsel</I></FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exhibit&nbsp;Index </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit&nbsp;No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release of StemCells, Inc. dated March&nbsp;13, 2012</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d314798dex991.htm
<DESCRIPTION>PRESS RELEASE OF STEMCELLS, INC.
<TEXT>
<HTML><HEAD>
<TITLE>PRESS RELEASE OF STEMCELLS, INC.</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px">


<IMG SRC="g314798g06s52.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>STEMCELLS, INC. REPORTS FOURTH QUARTER AND YEAR END 2011 FINANCIAL RESULTS AND </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PROVIDES BUSINESS UPDATE </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NEWARK, CA (March 13, 2012)</B> &#150; StemCells, Inc. (NASDAQ: STEM), a leading stem cell company developing and commercializing novel cell-based
therapeutics and tools for use in stem cell-based research and drug discovery, today reported financial results for the fourth quarter and year ended December&nbsp;31, 2011 and provided a business update. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;The StemCells team made significant progress in 2011 with regard to two critical goals for the Company, namely accelerating and broadening our
HuCNS-SC neural stem cell clinical trial agenda for diseases of, and injuries to, the central nervous system, while at the same time reducing our operating cash burn. We are now uniquely positioned as the only stem cell company pursuing clinical
trials for disorders of all three organs of the CNS, the brain, spinal cord and eye, &#148; said Martin McGlynn, President and CEO of StemCells, Inc. &#147;We have strong preclinical data underlying all our clinical trials, much of which has already
been published in peer-reviewed journals, but we realize that the true test of our proprietary cell-based technology will be in the clinic. In this regard, I am pleased to confirm StemCells remains on track to report safety and efficacy data from
our recently completed Phase I Pelizeaus-Merzbacher disease trial at the European Leukodystrophy Association meeting to be held in Paris, March&nbsp;31-April&nbsp;1. We are confident that executing our clinical trial agenda, while controlling our
cash burn, is the best way to build lasting shareholder value. &#148; </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Fourth Quarter and Recent Business Highlights </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Therapeutic Product Development </U></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">In February 2011, the fourth and final patient in our Phase I clinical trial in Pelizaeus-Merzbacher Disease, was enrolled and transplanted with our
proprietary HuCNS-SC<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> cells (purified human neural stem cells). This trial, which is being conducted at UCSF
Benioff Children&#146;s Hospital, is the first to evaluate neural stem cells as a potential treatment for a myelination disorder. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">In March 2011, we initiated a Phase I/II clinical trial of our HuCNS-SC human neural stem cells in chronic spinal cord injury. The trial is expected to
enroll a total of 12 patients who are three to 12 months post-injury, and will include patients with both complete and incomplete injuries as classified by the American Spinal Injury Association Impairment Scale (AIS). The trial was authorized by
Swissmedic and is being conducted at the Balgrist University Hospital, University of Zurich, a world leading medical center for spinal cord injury and rehabilitation. </FONT></P></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">In April 2011, we entered into a collaboration with Frank LaFerla, Ph.D., a world renowned leader in Alzheimer&#146;s disease research, to study the
therapeutic potential of our HuCNS-SC cells in Alzheimer&#146;s disease. Dr.&nbsp;LaFerla&#146;s published research has shown that mouse neural stem cells enhance memory in a mouse model of Alzheimer&#146;s disease, and the goal of our collaboration
is to replicate these results using our human neural stem cells. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">In June 2011, at the International Society for Stem Cell Research (ISSCR) 9th Annual Meeting, we presented evidence of engraftment, migration and the
long-term survival of our HuCNS-SC cells following transplantation into patients with a severe neurological disorder. Importantly, the results show that the cells can persist following the cessation of immunosuppression. The data support our premise
regarding the viability and utility of neural stem cell therapy as a potential treatment for a wide range of CNS disorders. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">In September 2011, the first patient in our Phase I/II clinical trial in chronic spinal cord injury was enrolled and successfully transplanted with our
HuCNS-SC cells. This landmark clinical trial has a unique design, in which patients with progressively decreasing severity of injury will be treated in three sequential cohorts. The first patient has an injury classified as AIS A, with complete loss
of sensation and mobility from the waist down. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">In November 2011, we reported that an interim review of one patient&#146;s MRIs from our Phase I PMD trial showed changes consistent with the
development of new myelin in the regions in which the HuCNS-SC cells were transplanted, and that the safety data suggest the procedure and cells have been well tolerated. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">In December 2011, we successfully completed the enrollment and dosing of the first cohort of patients in our Phase I/II clinical trial in chronic
spinal cord injury. The first cohort of patients all have spinal cord injury classified as AIS A, the most severe level. We also announced that enrollment for the remainder of the trial, which will include patients classified as AIS B and
AIS&nbsp;C, would be open to patients living in the United States and Canada. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">In January 2012, we published preclinical data demonstrating that our HuCNS-SC cells protect host photoreceptors and preserve vision in a
well-established animal model of retinal disease. Moreover, the number of cone photoreceptors, which are responsible for central vision, remained constant over an extended period. The preclinical results are highly relevant to human disorders of
vision loss, the most notable of which is dry age-related macular degeneration (AMD). The data was featured as the cover article in the February 2012 issue of the international peer-reviewed <I>European Journal of Neuroscience</I>.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">In January 2012, the U.S. Food and Drug Administration (FDA) authorized the initiation of a Phase I/II clinical trial of our HuCNS-SC cells in dry AMD,
the most common form of AMD. AMD is the leading cause of vision loss and blindness in people over 55 years of age, and approximately 30&nbsp;million people worldwide are afflicted with the disease. There are no approved treatments for dry AMD.
</FONT></P></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">In February 2012, the fourth and final patient in our Phase I PMD trial completed the twelve-month follow up and evaluations required by the trial
protocol. Results of the trial will be reported at the European Leukodystrophy Association meeting to be held in Paris, France, March&nbsp;31-April&nbsp;1, 2012. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><U>Tools and Technologies Programs </U></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">In January 2011, we launched STEM24&#153; and STEM133<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>, two new antibody reagents that have utility for the isolation and detection of a range of different human cell types. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">In March 2011, we launched nine new products and three related kits to facilitate stem cell research. This new line of purified nucleic acid and
protein stem cell lysate products enable stem cell researchers to more accurately test and validate stem cell lines and associated genes and gene products. These new reagents are serum-free and are produced by purification of the DNA, RNA or protein
content of the lysates of homogenous mouse stem cell lines. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Also in March 2011, we launched three new cell culture supplements for the derivation, culture and differentiation of human and mouse embryonic stem
cells, induced pluripotent stem cells, and tissue-derived neural stem cells. These new supplements provide researchers with additional choices to use either a defined, serum-free, or a defined, serum-free and animal component-free version of culture
supplements that are considered to be fundamental reagents for stem cell research. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">In July 2011, a collaborative study was published which used commercially available SC Proven serum-free cell culture media for the reproducible and
robust production of large numbers of genetically stable, self-renewing cells that retain true multi-potent biological function over extended culture periods. This work overcame a key hurdle to the use of non-immortalized cells for regenerative
medicine. The paper was published in a special edition of <I>Neurochemistry International </I>dedicated to &#147;The Potential of Stem Cells for 21st Century Neuroscience.&#148; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Other Business Activities </U></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">In January 2011, we sold 1,000,000&nbsp;shares of our common stock to selected institutional investors at a price of $10.00 per share. We received net
proceeds, after deducting offering expenses and fees, of approximately $9,400,000. The investors were also granted an option to purchase an additional 600,000&nbsp;shares at $10.00 per share. The option was not exercised and expired on
February&nbsp;18, 2011. </FONT></P></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">In July 2011, as part of our cost reduction program, we relocated our corporate headquarters and U.S.-based research and development operations to
Newark, California. Our new facilities comprise newly constructed, custom designed laboratory and office space, and house the majority of our U.S. workforce. As previously reported, we estimate annual savings in excess of $1 million from this move.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">In July 2011, following the affirmative vote of our stockholders at our Annual Meeting, we effected a one-for-ten reverse stock split which reduced the
number of shares outstanding from approximately 139&nbsp;million to approximately 13.9 million. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">In July 2011, we received notification from The NASDAQ Stock Market that we had regained compliance with the minimum bid price requirement needed to
continue listing on the NASDAQ Global Market. The NASDAQ Listing Rules require the Company&#146;s stock to evidence a closing bid price of $1.00 per share or more for ten consecutive days. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">In September 2011, the California Institute of Regenerative Medicine (CIRM) awarded us a &#147;Disease Team Therapy Development Planning Award&#148;
totaling approximately $100,000. We were one of only four companies to be awarded a disease team planning grant. The funds helped us and our collaborators prepare and submit an application for a &#147;Disease Team Therapy Development Research
Award&#148; to develop our HuCNS-SC cells as a potential treatment for Alzheimer&#146;s disease. A Research Award may be up to $20 million, payable over four years, to fund preclinical and IND-enabling activities with the aim of starting human
clinical trials within a four-year window. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">In December 2011, we raised total proceeds, net of underwriting discounts and expenses, of approximately $9.2 million through a public offering of
8,000,000 units and 8,000,000 Series B Warrants. The combination of units and Series B Warrants were sold at a public offering price of $1.25 per unit. Each Series B Warrant gives the holder the right to purchase one unit at an exercise price of
$1.25 per Unit and is exercisable until May&nbsp;2, 2012. Each unit consists of one share of our common stock and one Series A Warrant. Each Series A Warrant has a five-year term and gives the holder the right to purchase one share of our common
stock at an initial exercise price of $1.40 per share. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Fourth Quarter 2011 Financial Results </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">For the fourth quarter of 2011, the Company reported a net loss of $7,212,000, or $(0.47) per share, compared with a net loss of $8,957,000, or $(0.70)
per share, for the fourth quarter of 2010. Loss from operations in the fourth quarter of 2011 was $7,313,000, which was 5% lower when compared to the $7,706,000 loss from operations in the fourth quarter of 2010. Included in net loss and loss from
operations in the fourth quarter of 2011 is a charge of $655,000 for the write-off of an acquired intangible asset. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total revenue during the fourth quarter of 2011 was $541,000, compared to $699,000 in the same period of
2010. The decrease of 23% from 2010 to 2011 was due to both lower product sales and lower licensing and grant revenues. Total revenues in the fourth quarter of 2010 were higher due to a particularly strong quarter in our SC Proven business as well
as the receipt of a milestone payment under a licensing agreement of approximately $438,000 in 2010. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total operating expenses in the fourth
quarter of 2011 were $7,807,000, compared to $8,341,000 in the fourth quarter of 2010. Excluding the impairment of the intangible asset, which is included as an operating expense, total operating expenses in the fourth quarter of 2011 were
$7,152,000, or 14% lower than the same period in 2010. In the fourth quarter of 2011, research and development expenses totaled $4,834,000, or 18% less than in the same period of 2010, while selling, general and administrative expenses totaled
$2,290,000, or 8% lower. The significant reduction in operating expenses was primarily attributable to the Company&#146;s cost containment efforts, including the reduction in force effected in May 2011. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other income, net in the fourth quarter of 2011 was $102,000, compared to other expense, net of $1,449,000 in the fourth quarter of 2010. The change from
2010 to 2011 was primarily due to changes in the estimated fair value of warrant liability, as well as the receipt in 2010 of $978,000 in grants under the federal government's Qualifying Therapeutic Discovery Project (QTDP) program. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Full Year 2011 Financial Results </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">For
the full year 2011, the Company reported a net loss of $21,329,000, or $(1.50) per share, compared with a net loss of $25,244,000, or $(2.05) per share, for 2010. Loss from operations was $28,076,000, which was 4% lower when compared to $29,360,000
for 2010. Included in net loss and loss from operations in 2011 is a charge of $655,000 for the write-off of an acquired intangible asset. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total revenue in 2011 was $1,221,000, compared to total revenue of $1,427,000 reported in 2010. In 2011, however, product sales revenue from the
Company's SC Proven line of media and reagents increased 33% over 2010, driven both by higher unit volumes as well as the introduction of new products. Licensing and grant revenue was lower in 2011 primarily due to the receipt of a milestone payment
under a licensing agreement of approximately $438,000 in 2010. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total operating expenses in 2011 were $29,082,000, compared to $30,618,000 in
2010. Excluding the $655,000 write-off of the intangible asset, total operating expenses declined 7% compared to 2010. Research and development expenses in 2011 were $19,938,000, a 5% decrease compared to $21,019,000 in 2010. Selling, general and
administrative expenses in 2011 were $8,202,000, a 13% decrease compared to $9,377,000 in 2010. The reduction in operating expenses was primarily attributable to the Company&#146;s cost containment efforts, including the reduction in force effected
in May 2011. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other income in 2011 was $6,748,000, compared with $4,116,000 in 2010. Other income in both periods was primarily driven by a
decrease in the estimated fair value of warrant liability, which totaled $6,612,000 in 2011 and $3,005,000 in 2010. Other income in 2010 also included $978,000 in grants received under the QTDP program. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">For the full year 2011, cash used in operations totaled $22,058,000, compared to $24,520,000 in 2010.
However, in the last six months of 2011, which includes the effect of the reduction in force effected in the second quarter, cash used in operations was slightly less than $9 million. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">At December&nbsp;31, 2011, the Company's cash, cash equivalents and marketable debt securities totaled $16,592,000. In the first quarter of 2012, the Company has also received aggregate gross proceeds of
approximately $1.4 million from the exercise of warrants and receipt of a licensing fee. Including these proceeds, the Company&#146;s <I>pro forma</I> cash balance at December&nbsp;31, 2011, would be approximately $18 million. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Conference Call </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">StemCells will host a
live conference call and webcast today, March&nbsp;13, at 4:30 PM Eastern Time (1:30 PM Pacific Time) to discuss its financial results and recent business activities. Interested parties are invited to listen to the call over the Internet via the
Investors section of the Company&#146;s website at <U>http://investor.stemcellsinc.com/phoenix.zhtml?c=86230&amp;p=irol-irhome.</U> An archived version of the webcast will be available for replay on the Company&#146;s website beginning approximately
two hours following the conclusion of the live call and continuing for a period of 30 days. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About StemCells, Inc. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">StemCells, Inc. is engaged in the research, development, and commercialization of cell-based therapeutics and tools for use in stem
cell-based research and drug discovery. The Company's lead therapeutic product candidate, HuCNS-SC<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> cells
(purified human neural stem cells), is currently in development as a potential treatment for a broad range of central nervous system disorders.&nbsp;The Company recently completed a Phase I clinical trial in Pelizaeus-Merzbacher disease (PMD), a
fatal myelination disorder in children, and the trial data will be reported in late March. The Company is also conducting a Phase I/II clinical trial in chronic spinal cord injury in Switzerland and has received authorization from the FDA to
initiate a Phase I/II clinical trial in dry age-related macular degeneration (AMD). In addition, the Company is pursuing preclinical studies of its HuCNS-SC cells in Alzheimer's disease.&nbsp;StemCells also markets stem cell research products,
including media and reagents, under the SC Proven<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> brand. Further information about StemCells is available at
http://www.stemcellsinc.com.</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Apart from statements of historical fact, the text of this press release constitutes forward-looking
statements within the meaning of the U.S. securities laws, and is subject to the safe harbors created therein. These statements include, but are not limited to, statements regarding the future business operations of StemCells, Inc. (the
&#147;Company&#148;); the timing and prospect associated with beginning to detect potential clinical benefit from the use of the Company&#146;s HuCNS-SC cells; the prospect for continued clinical development of the Company&#146;s HuCNS-SC cells in
CNS disorders; the prospect for </I></FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>
growth in the Company&#146;s product sales; the timing and nature of the final data from the Company&#146;s Phase I clinical study in PMD; the timing of patient dosing and possible outcomes of
the Company&#146;s Phase&nbsp;I/II clinical study in spinal cord injury; the Company&#146;s ability to apply for, and possibly secure in 2012, funding from the California Institute of Regenerative Medicine; the adequacy of our existing supply of
HuCNS-SC cells to complete our ongoing and planned clinical trials; and the timing and prospects associated with initiating a clinical trial in age-related macular degeneration. These forward-looking statements speak only as of the date of this news
release. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Such statements reflect management&#146;s current views and are based on certain
assumptions that may or may not ultimately prove valid. The Company&#146;s actual results may vary materially from those contemplated in such forward-looking statements due to risks and uncertainties to which the Company is subject, including
uncertainties with respect to the fact that additional trials will be required to confirm the safety and demonstrate the efficacy of the Company&#146;s HuCNS-SC cells for the treatment of spinal cord injury, PMD or any other condition; uncertainties
about whether myelination formed by donor cells, if any, will have any biologic effect; uncertainties about whether preliminary data in any Phase&nbsp;I clinical study will prove to be reproducible or biologically meaningful in any future clinical
study; risks whether the FDA or other applicable regulatory agencies will permit the Company to continue clinical testing in spinal cord injury, PMD or in future clinical trials of proposed therapies for other diseases or conditions such as
age-related macular degeneration; uncertainties about the design of future clinical trials and whether the Company will receive the necessary support of a clinical trial site and its institutional review board to pursue future clinical trials in
spinal cord injury, PMD, age-related macular degeneration, or in proposed therapies for other diseases or conditions; uncertainties regarding the potential for the Company to grow its SC Proven business and to advance the development and
commercialization of stem cell-based assays for drug discovery and development; uncertainties regarding the Company&#146;s ability to obtain the increased capital resources needed to continue its current and planned research and development
operations, including such operations of the Company for non-therapeutic applications, and to conduct the research, preclinical development and clinical trials necessary for regulatory approvals; uncertainties about the Company&#146;s ability to
secure funding from any governmental agency, such as the California Institute of Regenerative Medicine; uncertainty as to whether HuCNS-SC cells and any products that may be generated in the future in the Company&#146;s cell-based programs will
prove safe and clinically effective and not cause tumors or other adverse side effects; uncertainties regarding whether results in preclinical research in animals will be indicative of future clinical results in humans; uncertainties regarding the
Company&#146;s manufacturing capabilities given its increasing preclinical and clinical commitments; uncertainties regarding the validity and enforceability of the Company&#146;s patents; uncertainties as to whether the Company will become
profitable; and other factors that are described under the heading &#147;Risk Factors&#148; disclosed in Part I, Item&nbsp;1A in the Company&#146;s Annual Report on Form 10-K for the year ended December&nbsp;31, 2010 and in its subsequent reports on
Form 10-Q and Form 8-K. </I></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">CONTACT: </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rodney Young </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">StemCells, Inc. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Chief Financial Officer </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(510) 456-4128 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">David Pitts </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Argot Partners </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(212) 600-1902 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#150; more &#150; </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>StemCells, Inc. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Unaudited Condensed Consolidated Statements of Operations </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(in thousands, except share and
per share amounts) </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">(unaudited)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Three months ended<BR>December&nbsp;31</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Twelve months ended<BR>December&nbsp;31</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2010</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2010</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenue:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenue from licensing agreements and grants</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">395</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">519</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">558 $</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">928</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenue from product sales</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">146</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">180</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">663</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">499</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">541</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">699</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,221</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,427</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cost of product sales</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">47</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">64</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">215</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">168</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gross profit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">494</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">635</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,006</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,259</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operating expenses:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,834</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,923</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19,938</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,019</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Selling, general and administrative</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,290</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,487</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,202</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,377</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Wind-down expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">28</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(69</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">287</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">222</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Impairment of intangible asset</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">655</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">655</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total operating expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,807</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,341</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">29,082</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30,618</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss from operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7,313</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7,706</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(28,076</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(29,359</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other income (expense):</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Qualifying therapeutic discovery project grant</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">978</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">978</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Realized gain on sale of marketable securities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">84</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Change in fair value of warrant liability</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">112</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,179</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,612</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,005</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest income (expense), net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(12</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(57</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(67</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other income (expense), net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(31</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">109</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">199</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total other income (expense), net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">102</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,251</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,748</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,115</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7,211</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8,957</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(21,328</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) $&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(25,244</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Basic and diluted net loss per share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.47</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.70</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1.50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">) $&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Shares used to compute basic and diluted loss per share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,244,718</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,712,402</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,187,885</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,330,299</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>StemCells, Inc. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Unaudited Condensed Consolidated Balance Sheets </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(in thousands) </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,&nbsp;2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,&nbsp;2010</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ASSETS:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Current Assets:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash&nbsp;&amp; cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13,311</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19,708</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Marketable securities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,281</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">191</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other current assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">796</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,270</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total current assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17,388</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,169</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Property, plant and equipment, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,055</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,627</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Goodwill and other intangible assets, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,906</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,874</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other assets, non-current</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,856</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,932</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25,205</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30,602</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>LIABILITIES AND STOCKHOLDERS&#146; EQUITY:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Current liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,653</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,528</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fair value of warrant liability</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,042</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,672</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other non-current liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,785</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,921</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stockholders' equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,725</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,481</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total liabilities and stockholders&#146; equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25,205</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30,602</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g314798g06s52.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g314798g06s52.jpg
M_]C_X0`817AI9@``24DJ``@``````````````/_L`!%$=6-K>0`!``0```!D
M``#_X00::'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+P`\/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B`\
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835`@0V]R92`U+C`M8S`V,"`V,2XQ,S0W-S<L(#(P,3`O,#(O,3(M
M,3<Z,S(Z,#`@("`@("`@("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO
M+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<$U-/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C`O;6TO(B!X;6QN<SIS=%)E9CTB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87`O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(@>&UL
M;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O(B!X;6QN<SID
M8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B('AM<$U-.D1O
M8W5M96YT240](GAM<"YD:60Z0T(V.#4W-3(V0T9!,3%%,4)!03)!.3!$144R
M,35#,#@B('AM<$U-.DEN<W1A;F-E240](GAM<"YI:60Z0T(V.#4W-3$V0T9!
M,3%%,4)!03)!.3!$144R,35#,#@B('AM<#I#<F5A=&]R5&]O;#TB4%-C<FEP
M=#4N9&QL(%9E<G-I;VX@-2XR+C(B/B`\>&UP34TZ1&5R:79E9$9R;VT@<W12
M968Z:6YS=&%N8V5)1#TB=75I9#IB,V9C830R,"TS,S`S+31F.#@M8C`X-BUF
M9&8V-C1E,SAC8C`B('-T4F5F.F1O8W5M96YT240](G5U:60Z860T-F0Y93DM
M8SDQ,RTT96-C+6)C96(M8V0R93%A,S)A8C1C(B\^(#QD8SIC<F5A=&]R/B`\
M<F1F.E-E<3X@/')D9CIL:3YL;&]G86YA=&AA;CPO<F1F.FQI/B`\+W)D9CI3
M97$^(#PO9&,Z8W)E871O<CX@/&1C.G1I=&QE/B`\<F1F.D%L=#X@/')D9CIL
M:2!X;6PZ;&%N9STB>"UD969A=6QT(CY-:6-R;W-O9G0@5V]R9"`M($58.3E?
M,5\S-#@T,SDQ+D1/0U@\+W)D9CIL:3X@/"]R9&8Z06QT/B`\+V1C.G1I=&QE
M/B`\+W)D9CI$97-C<FEP=&EO;CX@/"]R9&8Z4D1&/B`\+W@Z>&UP;65T83X@
M/#]X<&%C:V5T(&5N9#TB<B(_/O_M`$A0:&]T;W-H;W`@,RXP`#A"24T$!```
M````#QP!6@`#&R5''`(```(``@`X0DE-!"4``````!#\X1^)R+?)>"\T8C0'
M6'?K_^X`#D%D;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!
M`0$!`0$"`0$"`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#_\``$0@`5`&P`P$1``(1`0,1`?_$`.L```$$
M`@,!`0`````````````("0H+!@<#!`4"`0$``00#`0$```````````````4&
M!P@#!`D"`1````8!`P(#`P0($0@$#P$``0(#!`4&!P`1"!()(1,4,14602(R
M"E$CMA>76!DY87&!0C,DE-355W>WUQ@X>!I28B65)G;6-[)SDU21H7)#4],T
M9#559396ED=G$0`!`@0"!0<%"`T)"0$!`0`!`@,`$00%$@8A,4$3!U%A<8&1
M(A2AL3(5"-%"4F)R([,7P8*2TC.3TU1T518W&**R8W,DE#5U-O#"0U.#-&2T
M)>&C)O_:``P#`0`"$0,1`#\`G\:((-$$&B"#1!!H@@T00:((-$$&B"#1!!H@
M@T00:((-$$&B"#1!!H@@T00:((-$$&B"#1!!H@@T00:((-$$:ERYF_&N#X`9
M_(=B;Q2:I3A&Q2.SJ=FEB!N+>(BR&!=T??VG'I2)[3G*'CIH9QSWEC(EO]89
MCJ4M),\#8[SKI&QML:5'E.A(VD0D7B^VRQ4_B+BX$`^BG6I1Y$IUGS#:1#1F
M5NYSD>><.V&)ZY%TF'$3IMYJ;2).V94GT07*V,(0K`X[=0%$CD2[["(^W5/,
MV^U)F:X.+I\HTS5#1Z@XZ`Z\1RX3\VCH(7*(>NW%&YU"BW:&T,,;%*[R^F7H
MCL,(CLF=LZ9(<G1G\BWFRJ'$QO=C=\\,V)YA@$WDQ$61-NB4Q@#P(D`>`!J#
M+GGW/F9G2BX7*OJE'W@4HC3R-H`2.I(ACU5^OUS44U%2^Z?@@F74E.CL$>"A
MCG+;U$SQO1\A.6^PG,X3K\^8FW3UB83>F_R1WUH-Y:S>^@O-T%Q4WRAIV7+R
M1KIMMW6G&EBI*>7`OW([4;=LR8Q6(I&V'(5&5;F)TF*O-PA2C[2$'SRHI&*8
M#;=([@(#MMXZRTM\SIE98535-QH%)/*ZUYY"/35=>;606G*FG(YU)\\H57C7
MN-9]IBC="TN(?)4.0Q052G6A(^9!'?Q]/,Q)$`.H!/8*Z*W4.VX^W4M99]I3
MB%95)1=5,W.B&L.I"')<SC<M/RTJYS#MMG$G,-$0FK**IGXPDKJ4F7E!AV?`
M/,'$N?DT8Z(?GK-V\KJ<TJP*HHR*A@#=0\,Z*8K6<;EV]J6RI0\3)E#Q&W?#
MWC+E#B$E--1N&EODM-,\0%GE+:O1='R>\-J1$N9>SE:,P@-,JW5=+2VN0/VI
MU*'1IY1&/<@>;N)L&*.X%)<UYOC<#)GJT`Y1%.,7V^:6P2H^8VC#!ON*(`HX
M^R0H"`Z3N(?'3*&0U+MZ%&OS`G1N&B)(/],YI2CY/>7\4:XU\PYZM%A)ITG?
MUX]X@CNGXZM2>C2>:&I,B]PSD3=U5DX69C<<Q)Q.!&549)G?>4.X`"\Y*$=/
M14`/'J1!OX_)JI69?:,XD7U:DT+[5MHSJ2PD%4N=U>)4^=."(EN7$7,E<HAA
M::9GD;&GK4J9[)0E]]9<M9+<F7?R]^O+E<XG,L=2<G3'/OU"85$BKEWW+]GY
M-16_<\W9G<+C[UPKW5&<YNNS/2)PUG*J[W-6)Q=0^H[>\OW8^E\>9=C4R/7%
M(R&R2((*$<G@)],"F*45"F*<&VX"!2[@/Z&OKF7,X4J0^Y0W%"1I"BTZ.?X,
M"K;>&AO%,5*1RX%^Y&9U#D+GS&[A)O!Y(NL&*73TQ$DZ7<,^D@`!>N&FD5VQ
M@`/#<4O9I:L_$7B!EIT-T%SKF,,OFUJ)3^+=!3_)C=H\Q9@MA":>I?;E[TF8
M^Y4"/)"\L8]RJ]1Z`LLET^+MH$0."$M`*^X))1<"[)>M:J@ZCE$S&#YQDBI"
M&^X%^34_96]IR_T[>YS/1M5@"3)QH[I9.S$DXD$<I2$]$/\`M?$VX-C=W1E#
MVC0I'<5/G&E/9*/'M/.?-5T<&)"N8NAQ9SF`C:#:D=R(I"(@'J):2(NH"G3X
MB*)$=A]FM.Z\><\7Q930J:M]+L2TD*7+G<7,S^2$QAJ\]WNM40P4T[7(D3/6
MHS\@$8M&6;(-W7!61F;7:5E!V$ZJ\E)[B`B(EW)YA2])OD\-M(]+=<Q7U>.J
M?K*M9.LE:_-.--NJN-<N;JWG3TE4;YK-:N#8J*SB"L2">Q3`HK'2!"^P#%-N
M*7R@&X:D*V6N\M)2MRGJ4IT:2A8^Q#@IJ6M3(J;<`Z#"G:3/V)@9%$)*2;AN
M`"W6.J!/#[*"X"4?#[(:E"QW"Y4\D;UU/,2?,8=-"_4-D#$H<Q__`&%45Z3<
MR#<!="0YP(`]92@01^3YP!\W?](`U+5MJG:EH;V15RP[*9U3B9JUQD>E.-F#
M1!!H@@T00:((-$$&B"#1!!H@@T00:((-$$&B"#1!!H@@T00:((-$$&B"#1!!
MH@@T00:((-$$&B"#1!!H@@T00:((-$$&B"#1!!H@@T00:((2GRKY0U[CC4"+
M`1"8OM@2<)5*MBJ``8Z9>A29E0(/FHPS%0P=0AL98^R91WW$L2\6>*ENX:V<
M+DE[,%0"*=F>T:W'-H;2=>U1[HVD-/-F::;+5'BD%W!P'=H_WE<B1Y3H$1[Y
MR>RGR$R(5W)*S=^OMG=%;,639(RZH%$WVIC&,40*VC8QH0?HE`B29`$QA]IM
M<ZZ^X9KXB9D#U47[AF"J7A2E(F>9"$#0A">022D:2=9BNS]1=<Q7+&Z5U%P=
M,@!IZDC4E(Z@-9AU7`?;0@F#5G8<]/U)J54*1<M&@GBC:&8;[&!&8F&XIO)-
M</8<C<R*0"'TSAOJV7#_`-F&@IVD7'B`X7ZLR/A6E%+:.9QP24L\H04IYS$L
M9?X8L-H349@5C=.G=(,DCF4H:5'HD.<PY73L78YQ^T18TJDUFM-VY0*E[JB&
M;=<`#;83NP2%VJ;P]ICF'?5G+-E3+6764L6.AI:5M.K=MI!ZU2Q'K)B3J*U6
MVW("*%AII(^"D`]NORQGFG!&_'E2T%"3[8S.<AXN9:&*)3-I5@UD$!*8-C`*
M3M)4GC^EK4K*"AN#>YKV6GF3[UQ"5CL4"(Q/,,5"<#Z$+1R*`(\L(FS#V^<&
M9(;.GE6C!QE:#E440DJR3_0R[@VY@"2KJI_1'3,?VF;^G4\=]S;`&H.SG[.V
M0\S-+>M+7JNZF9"V/P9/QV2<,I[48#TZH8UYX=V&YI*Z1/A:O8I'HD\Z-79(
MPRKF?!&4..5L0CK6U<,@,X.O6;E!K.4XJ6!`=RN(J22\I=D_2*(&.@<2+I;^
MP0^<-'\[9!S5PUNZ::[H4CO38J6B0VY+4IM8D4K&LI,EIZ-,0C>[!=<M5@;J
MP4Z9H<3/"J6U*M8(VC01'[A'C]DWD195HVG,3G:(N`4L=OF#+A#1`KF\Q19^
M]$#K/9!8!$Q4$^M=0?$=@W-K[D;AWFCB/=%4ME;)9"IO5#D]VW/22I6DJ6=8
M2)J.O5I@L>7KIF.J+5$GN`]]Q4\*9\IVGF&DP]3AWM]8-QNU;.[5&_?.M!/+
M46DK,F'N=LN78VT;7DCBR(F4X>!G`N%!VWW+OMJ[V3/9VR'EII+UV:]:W42)
M6^/FP?B,@X0.=>,]&J)NLW#NPVQ(75I\55;5+]$'XJ-7;,]$+:BH2&@FY6D)
M$1D.U*4I2MHM@U8(`4OT0!)JDD38/TM3G24-%0-[FA9:99'O4(2@=B0!#Y:8
M8ITX&$)0CD2`!Y(]36U&6,#N&+L<W]JJSNE)K-D16_9!E(AFX<;[;`8CL4@=
M)F#Y!*<!#3?O.5,M9A:+-[H:6I0K7C;23U*EB'483ZRU6VXH**UAIU)^$D$]
MNORPWME_MPP#Y49C"LS\-N%%TQ<56Q+N'L*"1U`!4\9)[+2+042CU`DKYP&V
M$`.7P#5=,X^S3;WU^,R._P"&<*A-AXJ4U(G24+TK3+7A5B!V$:(CN\<-:9:M
M]9%[I4]+:R2G[56DB7(9],;MQ%P;Q70&C9U;DS9#L8%(=9>5(9"!:K;`8Q6,
M,FIT*D*?P`[DRHF`-^DOB&GSD[@/E/+S*7KP#<KG($ES0TD_$;!D1/:LJ)Y!
M"Y9\B6FWH"ZP>)J9:2K0@="?=GU0L:,AHB%;E:P\7'Q;8A2D*A'LV[-("E#8
MH=#=-,H[!J:*6BHZ%L,T33;30&@(2$CL`$/-IEEA.!E"4)Y``/-'I:VHRQTG
M,<P>`(.F;9??VBJBF8WZAQ+U`/ZNL#M-3OB3R$*Z0(\+:;7Z:0>J/EI&M6)C
M>E**9#!MY?4)BE\=_F]0B8`_0WU\9I6J<_-"2>2/B&DM^AH$=_6Q&2#1!!H@
M@T00:((-$$&B"#1!!H@@T00W3W%.Y3A'MUXW862_E<V[(]O(]1QIB:"=MD)^
MU.69`!S*/W"_62!J<:LH0KI^H0^QS@FDFJH/2$@9`X=WGB!<%4]!)JWM2WSZ
M@2E`.H`#TEG8D'G)`TPRLZYYM62J$/UDW*YV>Z921B61K)^"@;5'H`)B&YG?
MZP#W%<O2K]:JY$KN!JPLJK[NK^,:W'`]8(G`R:8+6JRIS,R^<@F(")A$B?F`
M)BD*'S0MS9.!/#^TM)%53N5U2-:GEF1/R$84@>66LF*R7?C'G:Y.*-.^BC8.
MI+21,?;JQ*)\D]0A/-=[Q_<QKD@D_2YAY(F5""42LK,A5)F/4$A@-L=DM7TB
MJ`;V&\?$-+]1PCX<U#>[-IIT#E05I/;B,(K/$W/3+F,7-]1Y%8%#L*8E/]C?
MN9<L>>TEE^JY]KM#E(+%%?KKU'*58AG-9E92R6%^X10KLM#-7*U?':+8JN2J
M-T6Y@VV$#[_-K)QIX<96R,W255B<?2_5.+&Y6H+2$(`FM*B,7I$"1)ZHL#PG
MSWF+-[E33WA#*FJ="3O4I*25*.A)`.'4"=`'7#N'.C/EHXM\0^0'(6E0\!/V
MO$N.Y6X04-:"2*E>D7[!5L1)M+$B7L;)&9G!8>H$5TC^`;&#459*L=-F;-=!
M8*Q:VZ6JJ$MJ4B6(`STIQ`B?2#T1)&;+N_8,N5EYIDH6_3LE:0J922):Y$&7
M01TQ$:_Q0O-+^(+B]^X\K_TAZM7_``UY._/KGVL?DHKA]?F:/S.@['ORD'^*
M%YI?Q!<7OW'E?^D/1_#7D[\^N?:Q^2@^OS-'YG0=CWY2#_%"\TOX@N+W[CRO
M_2'H_AKR=^?7/M8_)0?7YFC\SH.Q[\I!_BA>:7\07%[]QY7_`*0]'\->3OSZ
MY]K'Y*#Z_,T?F=!V/?E(=C[/?>+Y`]Q'D-D7$.6<98<I4!3L-O\`(\?)8[0N
MJ4NYEVMUI]:38O#66TSC(8TS.Q+*"!$B*^:0GSNGJ`8MXL\)+#D"P4]VM535
MO/O5@:(=+>$)+;BYC`A)G-`&N4IZ(D3AIQ,O&=+T_;;BQ3-,M4I<!;QS)"T)
MD<2U"4E'9.<M,2,M5^B;(8P[H7>UQGP)L)<-X\JC3,_(([!&1FH!:7-&4_'+
M1\D1:+-<W[,BL@[EY%!0%DHUKY:GD;'561ZB=4U\->#=QSRQZWN#IH[#BDE6
M&;CI'I;L'0$@Z"LS$]`!D8B;/W%2AR@_ZLHFQ57G#-29R0V#JQD:23K"1(RU
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MBM^M]PN$<K8%8IDM+KQ4-!Q$$5TV9$4>`R667<./-$2]!4RE$#&&PO!SA19L
M[6ZHO5_6]X9M[=-MMG#B.'$I2E2)T3``$MLS$(<4^)-URE7,6FRI:\0XUO%K
M6,4A.24I3,#3(DDSYH];LK=X/)?.RY7_``3R'B:6QR;6*PG>*=:*DU5@D;A!
M(OT8^=BWL`JX=MRRT,=VBN"K84TS-S#U$Z@ZAP\8N$UNR32,7NP+>5;7'-VX
MA9Q;M4II4%2!PJD1(S,]1C)PMXEU^;JIZT7I+0KVV]XA:!AQIG)0*9D33,&8
MV;(D5:@")K@T01#-[@7UA+DSC[D_E'$G&"/QC"XWQ/;9*C$LL_7E+;-729KZ
M@,+!)**.WJ+&.C$IE)9%NDBB14"I"*AC"/A;S(G`7+E?ENFNN955*[C5-!S`
ME>!+:5:4C0"2<,B23+3H$5ASCQFOU'?ZBW6!-.BAIW"WB4G&I:DZ%'29`8I@
M`">C3#_?:9YTV/N`<4&.8;W`0%9R'`7*P8_N<;6!>%A73^!2CW#.>8-GR[IR
MP1FF,@0XH&54`BI#](@42E""^*>2:?(F:%6FA<<<H'&4.ME<L0"I@I)``.$B
M4Y"8EMB8N'6;7\Y9=%SJT(;K4.J;6$SPDID0H`S(Q`ZIG3.'-]1O#\C$KY=(
M3'5-LEXL;@K:%K$2\EGR@F`ICD:I&.1LCOX&<.U>E),/E.<`TCY@O=#ENRU-
M]N2L-%2LJ<4>4)&@#G49)'.1&G<*YBVT3M?4F3#2"H]6P<YU#GB+ODS(-SS]
ME*3M<FDZD[#;I=!A!0C8#K"S:K+%:0=>C$=S;$03,0FP?34$QQW$PCKE9FC,
M5[XA9J=N]4%NW*L>"&FDS.%).%IE`Y`)#G,R=)BJ]TN-=F&ZJJW05U+RP$I&
MF0)DE"1S:!TZ8?RXB<68/CY36[Z4;-)#)UA:(N+1-BF14\8"I`4+7(E8Q.M%
M@QZNE4Q=O4+;F$1+T@'03@[PHH.'=E345:4.9IJ4`ONR!P3$]RV=B4ZE$>FJ
M9,Q*+`Y.RHQEVB#CH"KHX`5J^#\1)V`;>4]4:JY_]S?CKV^*DBZR1)+6O)\^
MR4=4?#E7<-3VVPD*8R19.1,J8R%:K*:Y!*H_<ATB8!*B14X=.K49#X;9@S[5
M%-N2&K8V9.5"P<".8;5KY$CI)`TP^66%O'N^CRQ#8Y/]]WGWR&E9!*JY!2X\
M4154X1]1Q&D1E*)LQZB@G,WB12<V"4752V\T4A:H]8;III@/3JW>6N"&1;`T
MDU5.;A7`:7']*9_%;!"`.2>(\I,*:*1E`TC$>>&WG7+'E"]<K/'/)O/ZKA=3
MS%E0S1D5,#'\`$?+0LB:)/9["E`-2(G*V6D)"$VV@PC_`,=K[*(S[ML#T4]D
M+!X_]XSN%\?)-BY@>0=CR+76G016EY=,2_UYVV*8AE$0<R/3/LE%2D`HK(/"
M*E#V#OII7[A'D&_MJ2_0-T]0?^(Q\TL'ED.Z>@IE&)=,RL>C(\T2ZNVUWL<%
M<Y7$9B^]LV>$>1:R`%0I<G*$5J=^<)E$5CXYGGATU7+P0*)QBG0`^(7P3,X`
M!/JJ/$3@U>\E)5<Z$JK<O@Z7`GOM#9O4C4/CI[IVX=4)S]*MKO#2C_;7#O&2
M\9T[+=0E*1>8E*6@Y1/8Q1V3=L7)/%O(QCL"BJQD&A_G)JD\0]@[E$0&O69\
MKV7.%F=L5^9#U`Z.A25;%H5K2M)TA0ZY@D0BW.UT5XHUT->@+86.L'84G81L
M,<^/,>5+%M2B:52HEO#P4.W(BBBB0OG.ENDH+OWZX`!W<@[.7J55/N8P_8``
M`,F7,N6C*EH9L=C92S0,I``&M1VK6=:EJUJ4=)Z)1ZMUNH[51HH:%`13H&@;
M2=I)VD[3#7G<)[R?&?@:=[1C'5S%GHK;S$L44Z29IEKQU2=39;(-D$'36II'
MW`Q6WE+OU2#N5`"CUZG3(/"',>>`*W11V.?X=P'O\NZ1H*^F82/A3T0K,TSC
MNG4CEB*-G_OZ=Q',\B]&K9%A,`UA183,(+$\$R;R+-(`Z"E7MMC)-3;Q4Y0W
M./4F3KW$A2AL`6BL7`OA_9VQXFG77U(&E3ZB0>A",*1Y^4F%%%&RG6,1YX1B
MAW,.?J$L,TAS*SL$J*AE!<#>5E2B<P`4PBS5148B`E#82^5T_H:=ZN'&1"UN
M56BAW7)N_LSGY8R;AGX([(>L[5/=R[F.;N2>->.K]:K\BJ_97Q#6R4N\$G"S
MM(I4>8BUDNSRX55!F8WNUH&R9';9P1=PHFB0G6H&H<XH<*>'%FR[4Y@0';>^
MVGN);5B2XX?0;#:R=9UX2"`"29"-:HIV$(*_1,35-4YA+A-G,;,]BXZ<5>06
M=ZE%PLW9\1XGNE^@8BQE?&@9*4K<,YDF;.7+&.V,@9@NL@!501624Z1'I,`^
M.G%E&ST^8<T4%CJU+135=4VTI2)8@E:@"4S!$QLF"(]MI"W`@ZB8BU\<_K&_
M+G,7(3!.(K!A'CC&0.4\Q8TQU-R4,UR:67CXFZW&'KDB]BC/;VZ9%D6K21.=
M$5DE$O,*'44Q=P&S68?9[RG:+!779BMN*GZ6C>=2%%G"5-MJ6`J30,B1(R(,
MM1A071-I05`JF`3L]R)D^JAPF0:((-$$&B"(361/K,?,>GW?(=8C\$<9G+*H
M76ZUI@X>-,IBZ<LZU8I6'9KO!1OZ20N5V[`IE>@I2=8CT@`;!JY5O]G'*%71
M4]2Y77(+=9;60"S(%:$J('S6H$Z(5$T+1`,U:0.3W(F&X%OTIE;!F&,HSC-A
M'362<3XZOTQ'Q0.`BV,I<:?#V&09QH/%G+L&#9W(G(B"JBBGEE#J,8VXC4J^
M4+5KO=9;&"I3-/5.M)*I8BEMQ2`3*0F0)F0`GJA-6,*RD:@3&V-)4>8-$$&B
M"$"=P[N#8G[>F%S9'OB2EEN5C7<PN+\:1KI)M,7:PHH`JJ)UU`.$978=-0BK
M]Z8A@1(8I"E,HH0HOK(&0KKGZ\>KZ$ANC;`4\\1-+:)\FU:M24[=),@#&9EE
M3RL(U;3$'CD?WH^X)R*GI)VKFV9Q#4G;A3W=0,/'&HQ+!F*ACMFCB93\ZS3"
MZ)=@%99UU''Y`#8`NEE[@]D/+["4"B15U0&EVH^<43M(3Z"1S!.B%1%,R@:I
MGGA'D9S"Y?04B>:CN3?(AG('4!8[M7*U_<)BH"GF@;R'\PX9%#S/'8$P+\FV
MWAIW.92RF^WN7+;;RB4I;AH>4)!\L92TV=&%/9$E+L+=P+GCR8Y)RV&<K946
MRWA^KXUL%TM,K=(9@]MT0X2=QT/6B1MN8)1[A3U,Q($(=%R"X'0`X@'4'6%=
M...0\CY<RZB\6NE%)=G:E#:$MJ(;4)%2YMF8T)!D4RTRZ(T:MEIM&)(DHF&7
M>]1FBQYH[CW(A>:>N5HG&MA;8GIT<L=04(:!IL<T;.T6J1P*5+WE857CQ02E
M#K,L&XF`H#J7^#UGI[/P]MZ60`[4ME]P[5*<)(GT(PI')**&<4;H_=,[UI=)
M+3"PR@?!2@`&72K$H],/V=A'ME<7+GQAK_+?,="JN9\A9"L-N9UV+NL>TLE4
MH,'4K%)U8K1M6WP.(5]/2;N,4<N%W:"QT2F333`@E,8T'<<N(^9:/,CF5;0^
M[1T%.V@K4V2A;JEH"YE8DH)2"``D@'23.<2_P@R)8*JPHS'<V6ZJM>6L)"P%
M(;2A11()/=*B1,D@RT`2A_6Z<#.%60H9>!MW%3`<G'.$SI&!#%U1B'R1%``%
M/1R\+%QTNP,8`#<R"Z9O#VZ@NCSQG&@>#]+=*Y+@Y7G%#K2I12>L&)@JLH96
MK&BS46^C4@_T2`>HI`(ZB(ZG$7@SQVX.Q.18#CO5I"J0F3+>E<IV-?S3V<3:
M/&T<G&LHR)<R)E7S>$CT"G%!%558Q#+'^>._A[S7G7,&=':=^_NI=>IFMVDA
M(3,$S)4!H*B93(`G(:(\Y;RG9<J-OLV5M3;3[N-0*BJ1`D`"=(2-@).LZ8W!
MG["%'Y)X9R+@C)9)92AY1K3NJ6DD#)&AY@T2].D=<(^3(DN9DXZD0V.!#;?8
MTDV*\UN7;O3WNW8174S@6C$,2<0Y1HF(5+O:Z6]VUZTUV(TCZ,*L)D9'D,CY
MH9L_PW';7_[AGC\,4A_`^I=_B&XB?"H?[N/OHC#ZCLC<E9^./N0U_P!WSLX<
M-.$G"^P9WP@TRDE?8[(>-ZRV4MN1'EEAPB[3/EC94IXI9@V2.N9L;[6<3;IF
M#<-23PGXN9OSGG!%DO1IC0JIWEG=M!"L2$S3WIG1/6-L,+B3PRRQE7*Z[O:A
M4"L2\TD8W"I,EJD=$ALAE7M6\9<8\PN<F)./F8T[`KCRZ1.2GLVG5YI2O39E
MJICJR6B)])+)(N%&Q`E(I(5``@^8GN7PWWU,7$[,=RREDJJOUHW8KV5LA.-.
M-/?=0A4TZ)]U1ER'3$6</K#09ES936:YX_!.I=*L"L*NXVI8D=FD"?-$NK_#
M<=M?_N&>/PQ2'\#ZJI_$-Q$^%0_W<??19#ZCLC<E9^./N0L'A9VFN)7`C)%F
MRK@)KDE"UVRDN,?RQKG?'-JCAK[J=A;$J5LQ78-2H/?>,`WV5ZA$"=1=OG::
M6<.*6:L\VYNUWTTYI6G@ZG=M!!Q!*D:2"9B2CHY90YLK<.\N90K5W"SA\5#C
M1;.-S&,)4E6J0TS2/+RPY@8P%*8P^PH"8?E\`#<?_%J.=</J*I3E7>9W)O)_
MD1>[$^<2DW9\W9,=+O'8CZA9)&Y2T;%I*;F."?IXUH@D!0$2E`FP>&NG^6*)
MBVY;M]#3I"66J)D`#5^#25=I),<],PU;M??ZVK>)4ZY5NF9U^F0/(`(EN\9/
MJV/%V6PGCVR9^OF6+!DVUU2"L]B2IMC8U:MP+R=C6TF:`C&H14@X>IQ)7((F
M<JJ=2RA#'`I2B!0JOF3VB,RM7E^GL3%*W;6G5(1O$%:U!)(Q$X@!BE.0&@:(
ML;8>!M@<M3+]Y>J5U[C:5*P*"$I*A/"!(DRG*9.DQOS_``TW;U_^<\@/PE-O
M^'=(7\16??@4'XD_?0L?47DSX59^-'WL;:P-V"^$7';,^,\ZT*4S4M=,4VME
M<:RE.WUO(PQY5@FND@628E@D#.FHE<&ZB`<@C]G27?..><LP6>ILE<FC%'5-
M%M>%HA6$RG(XC(Z.2%*S\'\JV2YL7:C55&JIW`M.)P$3'*,/N0]SJ&8E2#1!
M%==W],BDR#W-\R-$53*-\<5G'6-R$ZCBDDXBJXG/O@2`WS0,+JS&`XE\.LHA
M[0V"_P!P,MYH.'%(HCO5#CKW4I>$>1$4JXP5OC<^521Z+#;376$XCY50ECMD
M\B3\6N=''C+3AX+*NI7=K3+P?S2H)&I-]*-7G3N53?-*WC@D$GIOL^E`/ETY
M^(]@&9LE7"U)$Z@LEQO;\XUWTRYS(I^VAOY$O?[/YLHKDHR8#H0Y_5N=Q4^8
M3"NJ+/<!`P`8H@8I@`0$!`0$!#<!`0\!`0US:B^L)@YJ9Y8\8N*.>\ZO5TD5
ML>8UL<K"%6,8I'=K=,S150C]R_/`9&SOVB.X?1Z]_8&G+DZQKS)FBALB`2*B
MH0E7,@'$X>I`480,TW=%AR]67=1D66%%/.LB2!UJ($58<C)/YF1D9F5=*O96
M8D'TM*/5S=2[R2DW2KY^[7-^N6<NUSG./RF,.NFC;:&6TLM`):0D)2!J``D`
M.@"4<_5K6ZM3KA)<4HDGE),R>LQ,,^JS9%37IO+/$JK@#KQ5IQ_D-FV$WSD6
M<]$2M=='(3;]C5=P`"(_Y7Z>JF>TS;RFKM5U`T*:=:)YTJ2L>1466]G^M!IK
MC;B=*7&W`.90*3Y4Q+0U5F+%PU?W1,E*Q%$I6+F#@4UKA+K3\XF0VQSPM?`I
M6*"@;^*#N6<`<?\`.;!JI_M59G71V"ARK3JDNM>+KH'_`"V?1!YE.&?2B(HX
MJ7,LT#%J;,B\LK5\E&H=!49_:PFSMI8@;W+)\WDR8:D<16-FB",059,#I'MD
MR50&SD`,(?;(N.154((=0%44*/@(`.HR]F+)K=ZS4_FBL0%4EL0`W,:/$.3P
MJZ4("B-<B1M`AL\,;,FMNJ[H\)LTH&'^L5J/VH!/21#EG./EI3^$W&C(_(&W
M%3>GK$<1C4J\904U;7>9D_H*K741*('`CV34*9<P;"FU34/O\W72?)65:O.>
M8Z>PTG=#JIK7\!M.E:^H:N4D"+`M-EU80(K3\HY.S1R\SK,W^Z.YO(^8,NVM
M%%LQ9).'[MW)2SP&L'5*S&I]8MHN/!8C5BU2`"))%`-O:.NC%LMMGRI9$4%&
M$4]II&M),@`E(FI:SM4=*E*.DF%M*4MHD-"0(EQ]O3ZNYB>EUFO9,YQ-CY*R
M1)-FTF7#+.2<,\?4D5DP53CK$^B72#VY3C<3`*_2LDP24+T%*L7<QJIY^X_W
M2LJ7+;DH^&MR24^((!=<YT!0(;2=F@J(TF6J$]ZM43A:T)Y>6'[(GA=Q!@HM
MO"17%SC\TBVR(H)-`Q!0E2"D8O2<%3KP*JK@ZA?IF4,8Q_UPCJ#7<XYM>=+S
MMSKRX3.>_=^PK1U1IEQPF949],-P<Q^P]PJY*P$M(8SI\?QNRN+5=2%MN-6)
M6-4</RIF%HWLU`242@7,6=4`*H+(C-P0@B8IA,`!J0LH\<,XY=?0W<GE7&US
M&)#QFL#:4.^D%<F(J!C.U5NH/>.)//#-/!KZNSG9;.3JS<L["GCC&V*+LDO7
M28XL@*6_*CZ`>IO8F=KDVSV<4JKJJI)*^I4`DF8>I,B:0@*H2_G7V@+&+(*;
M*K9J+C5,]_>H^;8"A)25I.AQ>L2'<VDG5&R[6HPR;$U$;=D32$4BH(I(%,H<
MJ*2:13K*'65,5,@$`RJR@F454,`;F,81$P^(^.J=J.(E1UDPF0S]WG.X:ZX'
M\;"-\?/$4L^9G7D*EB\YBIK?"[5NV(>SY`6;J`<JGPXT<ID:%,7H._<([[E*
M8!EK@_D!.>,Q8J\$V*C`6]\<D]QH'XY!*OB@\L;-,SO5][T!K]R('7'_``+F
M[FUG^%Q5CM%]=LJ9+F'\M,V&POG;E-JB907MDO%TFU"NG*<<P*J*SIP8#J'.
M8I"`8YRE&\%^OEER985W2X%+-KID!*4(`$]B&VTZ!,Z@-0UG0#"LM:&D8E:$
MB)N_$/L"<*,`5V)?9BK"?)3*GIVZTS8KT+M&F,I'IZUT*O1VCM*/3CDCF%,I
MGXO%5B%`QNDPB`4QS9QVSE?:A2+0[ZNM<SA0W+>$;"MPB<]O=P@:A.$IRK=6
M>[W4PX/.=NK@?8X4:_*<0N/0QHI"B(1^+*E"O^@2"3_XS"QL?,=?2/TO/ZM_
M'??QTPF.(&>*=[Q#5VN&\GM>6H?<J)3Y(Q!]X&84KMCSN*';NXH\*+-DNU\=
M\=FITIE(\82;]3,2$Z2*C(H%3MH"M+2ZKI_%01W2HN%&XK*@HOL81^:4`R9I
MX@9HSE34U+?ZC?-TV+#)(3B*M:EA,@I4M`,AH@<><=`"S.4+>TRXQ0@SNC?F
MY^:_]VW*WW*R&GSPS_>#9O\`,6/YXC*Q^&3\H17@<&/[;7#S^]%@3^=&KZOY
MG;_1EW_RRJ^A7"T[^"5\D^:+3+7,J$"#1!!H@@T014S9Q_YMYN_E6RQ]W%BU
MU-LO^%47Z*Q]&B'"CT1T#S1:$<-O[(7%7^[=@W^;&KZYJ9O_`-673_,:GZ9<
M(+OX57RCYX4CINQX@T00:((@&_6,,IV"Z=Q"4Q](.W9J_AK&%`@J['J"<K)!
M:YPC6]3<@U3$>@R[]>81264#Q,#4A!^@&KU^S[;&*/(":]L#?UE2ZI9VD-J+
M20>8820/C$[85Z)(#,]I,+S^K?<,>/N3*1E7DSDNI5G)&0ZQD)*A4V)M$>TG
M(NAL64+'S"\XC"R**[$;#-N9`/)='(8R""``ETF$XZ8WM#9POUMK:7+=N=<I
MZ!VGWKBD$I4Z2HI"<0D<*0-*1K)TS$HPUKJTD(3H3*)9LSCK'UCBUH.PT2FS
MT*X3\I>(F:Q"2D6NET]'EJL'K%=HHF!/#82"&VJLLW"OIW0_3OO(>&I25J2H
M=8(,)X409@F<:5PEPUXS\;[SD/(F"\1U;&%CRFSA&5T"IM3QD0_2KZ\DY8"R
M@TU/=4+U*R9Q6(S2025Z$Q,3<@#I8O.;\QYAHJ>WWNK=J:>E*BWC,U#$`#-7
MI*U:,1)$SITQ[6ZXL!*S,"(4_P!8'X6W?!7,&S\C&$,\>8;Y'.V-@:6-JW.>
M/KF1&L2QC++5995,#$9.))1@61:&4$`<%<*%+\Y,0U<7@/G"CO>4V\OK6!=[
M>"DH)TK:*B4+3R@3P*EJD#MBG'&3*]5:,RN7M"2;97$*"@-"7``%(/).6(3U
MS(V1H/MI=X'-W;O];14X!EEG`<]-'G)?&TH_/%2T#+.BIIR$S0["";E*)=R!
M$BBX:N$5FC@Y0/LF?<XKG$7A-9L_RK2XJEOJ$84O)&)*DC4EU&C$!L4"%#5I
M&B$?(O$JZY*G2!`J;.M6(M$R*2=:FU:9$[000>8Z8F'\0N]!P7Y>K1-<@\CA
MBO)TF#=$F-<ME;U65=R"Q1ZF=?G55U*S8C>:42IE1=%<J^`@B&X:J7FS@_G7
M*854/4_BK:F?SS$UI`Y5IEC1SS3(<L67RWQ0RGF0I9:?\/7JE\T])!)Y$J]%
M749GDAV`!`0`0$!`0W`0\0$!]@@/R@.HNB1(_=$$&B"&(OK&_P";*MW\L>%/
MNO3U-WL^?O':_0ZCZ.(DXV?Z$=_26/Y\1A.P/^=4X\?[O9N_F8NVK)<=/W8W
M#^LIO_8;B`^#_P"\*B^0_P#0+BQ8US_BZ\&B".-;]A5_ZM3_`*(Z^C7'Q6H]
M$5,F7Q`,T9;$?`"Y?R,81^P!;Y-B(_J`&NI5I_P>E_1&OHDQSKN7^*5/Z2Y]
M(J+%/'G=E[<45C^BQ<AR[Q,U?QU.K#!\U5D)0%6SQI",6[ENJ`10@"B*R9BF
M`!'80U0&OX6<0G:Y]UNU51;4\L@R&D%1(.O;%U:+B+DANC:;7<J8+2TD$3.@
MA(F-49C^5U[:_P".%B+_`%C*_P`%:U/JIXB?JFK[!]]&S]9&1OUG3=I]R%PX
MRR;0LRT.LY/Q?:(RZT"YQP2U7M,,HHK%S4<*ZS8';)19-%0R7GMSEW$H#N4=
M,NY6VNM%<Y;;FTIFO95A6A7I),IR/48=E!7T=THVZ^WN)=HW4S0M.I0U3'9&
M=:T8VX_!$``1'P``W$?L`&B"*L'F_?G.9>9W)Z]LE0?GN>?,C>X3E."@.(_X
MM?PU92`Y1,4_^C6S8FY=P';P\-=-<F4*;1E"VT2QA#-"UBYC@"E^4F.?N:ZQ
M5SS17U:#BWM8YAZ,92GR`1F?<(XG/^&G(U_B?]M!#RE"QSD:I/7!5`,I'7*K
M,)!ZDB=4H&6""M*3YB)Q]JC4=:>0LTHS?E]-TT;Y+[K2P.5M9`^Z1A5T*C9S
MGEU>6+VJW:=TIEMU!/(M`)^Y7B3U18'=KOD:7E-P4X]Y5<O0?63X*9TR[G%0
M55R7.B!\,3AGAQ$>IX]/'$=*#\HN/D]FJ(\2\O'+.=J^UI&&GWQ<;Y-V[WTR
MYA/".B+D9`O?[092HK@HS?W00Y\MON*GSF4^N&>OK.G(PE2P#ASC+$O3)3&7
M[FM?+*@DJ=-7X+QXF"35)8"_-6:25FET=R&_7-0$/HZEGV;\O^*OM9F-T?-4
MC.Z0?Z1W7T$(2>V(TX\WOPUGI;"V?G*EW>*^0WJZBHCLB+MC+B-*7;@QR<YA
MN"/"Q^&\AXAQ[6T4P$&LDYMLMO>7RO@`&^'(I['?*(?MT1VW+JRMRS6U1YUM
MN4DRWE73ONK.T!"?FQ]NH+^YYX@*@RXNKRG7YF,\%*^RVGD)6KYP_:@I^ZYH
M=-^K/9$-6.=%\H2BWEM,GX+GB%3\PQ0<2U*GH><8I^7U`1021KI\8!V$2]/A
MX".HS]HRWBIR4Q7`3735J>I+B5)/E"8D#@56[C-KU&3W7Z1764*"AY"J)W^J
M11;F(_\`W,9Q:2Y$,H=0QA1K="@D&Y1VZ2A*N7\BKT?IG-XZYY^U!7KJ>(Z*
M)4\%-;V@/^HI:S+KBO7$]]3N8TLGT6J=`'VQ*H<&[;M81@^-L?,@GLYN%JLD
MTJL)=C*(,W98)NF!M@ZDD31:@E]NPG-XZL3[,]K10\,VZT#YRLJWG">4)5N@
M.@;LRZ3$B<-*4,992][YYU:I\P.$?S3$?KZT7FF2]\\7^.[-T9&*"+MF9+"S
M*KX/W:STM,JBJJ13`(%CBLY;I$P"!A<>&PE'?IK[-%F;W-SS`L3=Q(IT'D$M
MXOMFCLYXE*@2)*7MU1H+ZM5Q9@LG<@\G\EK9%HR;/`,1%0-$3=()KM6N0KN@
M_%S-=*I3`1_"5AJ<&Q@\2'>&.&QBE$%WVB\SOVVP4V7*512NO6I3LC(EILB2
M>A2R,7R9;3'NN<*4!`V^:)OFJ80EP:((-$$&B"#1!%?Q]8<S+(9,[B-@I/JS
M+5_!^/*71H=N57J;IR$PR-<K(OY)3&(F\-)S@(*&V`YB-DP'P*`!?#@%9V[;
MD!NME)^MJ''%';))W:!T84S'.3RPL4:<+,]I,*N^KZYQX2<6JKG/+'(/-V/<
M=9=ND]%TBLQ]G<.DY9CCJ'9MY5XLU!&/=>4C/61QNJ)3AYA6:0&#YH::_'FR
M9SS/545KL%%45%I90IQ90!A+JB4@'2/10-&C1B/+&.L0ZX0E`)2//$D#\KCV
MVOQP,2?ZPE?X)U7GZJ.(GZIJNQ/WT:/AW_@F/3A.ZQV[K)-PM<@^6>*I*<L4
MQ%P$)&MG\F+F1F9I\WC(J/;@:+*47#U^Z32(`B`"8X>.L3W"[B!3LKJ'[55)
M8;0I2B0)!*02HG3J`!,!IW@)E)E#@VF%&&#1!"#.Z-^;GYK_`-VW*WW*R&GS
MPS_>#9O\Q8_GB,K'X9/RA%>!P8_MM<//[T6!/YT:OJ_F=O\`1EW_`,LJOH5P
MM._@E?)/FBTRUS*A`@T00:((-$$5,V<?^;>;OY5LL?=Q8M=3;+_A5%^BL?1H
MAPH]$=`\T6A'#;^R%Q5_NW8-_FQJ^N:F;_\`5ET_S&I^F7""[^%5\H^>%(Z;
ML>(-$$&B"(=?UD?@U=3WFM\Y*%"/9VH.JO%4/-)(UHJZ<560@5#MZI<I`B('
M4+`R,6N6/<+"`)M56J(G'9;<+;^SOG6C\$YDJN6E%6'5.T\S(+"M*VQ\8*&(
M#6H*,M4*5$Z);HZYZ(8BX)]PKD!V_<@O[EAJ1C9.N6CW>CD#&UF(NXJ5U91Q
MEO2'7],HF[B)MBFZ4!L_;CYB0'$IRJIB*8S?G?(-ASY0)H[PE2:AJ>Z>1(+;
M)URGH4DR$TG0=A!TQMNLH>3)6L:C$P7B/]82X9<@5HJKY=-+<9L@/Q1;`E>U
MT9+';U\IL0$V.0(])-K'E64`1+[R;LDR%$`,J)O#52\U<!,X6$+J;3@N5`G3
M\UH=`YVCI/VA43R0FN4;B-*>\/+#[\;)QTS'LI:'?LI6*DFJ+V.DHYT@]8/V
M;E,JK=VS>-CJMW+9=(P&(<AC%,4=P';4(.-N,N*:>2I+J3(@@@@C6"#I!'(8
MU(PS*.*L<YKHM@QGEBFP%^H=I9G83M7LK!&1BWZ!@^:)DE0ZD'*)OG)+)F(L
MB<`,0Q3``ZW+9<[A9JUNY6MYQBN:,TK09*!]P[0=!U$1IW"WT5UI%T%Q:0]1
MN"2D*$P?_P!Y"-(V1%SY<?5D:O+KRULX9Y;5J"RHKND,398]3,P!5#;J@S@;
MXQ`\S'H";YB*3YJ[`@"'4XV#5ELJ^T?4M)12YOI0Z!(%]B25=*FCW2>4I*?D
MQ`.8^`].X55&6*G='7N7IJ3T)<'>`Y`H'Y41<.37$OD'P\R`..>0F.9>@V(P
M*.X-^H)7];L[)LMT#+U"T,NJ-FV::H!N9$X+(FV!0A#;!JRV7,TV'-M!ZPL-
M0A^GU*&I:"?>N(.E)Z=!V$Q`-]R[><LUG@;RPIE_6DZTK`VH6-"AT:1M`B2]
M]7_[I^2;5D".X.<A+8_NC*6@GJ^!+G879WMDCGE;8+2$ACJ5E'`G=S+!:":J
MN(Y5<ZBZ'I3HB(D$HEKIQVX96ZFH59TL+265I6!4MH$D$+,@ZE(T).(@+`D#
M,'7$Z\'>(-=45B<IWIPNH4@^'6HS4"D3+9)TJ&$$I),Q(C5$OW53XLG!H@AB
M+ZQO^;*MW\L>%/NO3U-WL^?O':_0ZCZ.(DXV?Z$=_26/Y\1A.P/^=4X\?[O9
MN_F8NVK)<=/W8W#^LIO_`&&X@/@_^\*B^0_]`N+%C7/^+KP:((XUOV%7_JU/
M^B.OHUQ\5J/1%3%F$!-F7+Q0]I\N9)(&_@'4>\SA0W'Y`W'74JT?X12'_P`5
MGZ-,<Z[G_B=3^DN_2*AW.'^KS]RR=B(N;CJ?A92/F8UC*L3J9B8)J'9R+5)X
MV,HG[A,!%!16+N&X[#\HZBIWCWPZ8=4RX[6;Q"BD_P!G.L&1]]$CM<%\\O-I
M=0U2X%)!'SPU$3'O8]'_``Z7<X__``W"?X96'_#^L?\`$!PW_P"=6?W<_?QD
M^I//?_*I?QP^]B:)VX\&9`XT<'^..",J-8EED+&=!+7K4U@Y0DW$HR034N]Z
M6,JFBW(]1].\(/6!"AN(A\FJ?\0;U09CSG<+W;"HT%2_C05)PJEA2-*=FD&+
M0Y*M-78LJT5HK@D5;#6%4C,3Q*.L<Q$+9TS8=,:JSK>`QGA+,&1O-(B-#Q??
M;BFH<0`H+5NK2LP@'B(=1CK,R@4OM,80`/$=*EDHO65YI+?*>_J6F_NUI3]F
M$^[U?@+54UVK<T[B_N4%7V(J]N*=(7S=RPX^T42*KK9*SO0F:Q`#K44++7%E
M(N0/YA@`0.F!NOJ$`V$=]=*,T5J;-E:OK=`%-0NG[EL@10;+U(;KF*CI-9?J
MVQVK!,2H/K/O'!&1QS@+E'!Q@$=4B==X?N3ELV*1(E8LZ:TQ4CNE$P\"1UA9
M+H(E$`*4'QMA]@:K+[-F82W<*_++RNZ\@/M@GWZ))<ETH()^2(L%Q[L@714=
M_:3WFEEE9`]ZOO(GT*!`^5&*?5>>10JLN0_%66=@)V*T9FVE(**")@9O#,JG
M=FJ!!-TE21?!&.-@`1,=RH(^S6S[2M@DNWYG:&A0-.X><36V>S&.H1K<`[W-
M-;EYPZ1)]OH,D.#MPGK,,^=\_D>;D%W#LO)L7P/JAA%-CA>JE;+"X;"I4TS+
MV]V@4FZ9EGMQ>O"=1!$%$D$O'P``EK@KEX6'(-(5IPU=;.H7/0>_H;!Z&PDZ
M=1)B->+-[]<YTJ0@SIJ63".3N>F>M9/2`(D;4?A,MC[ZOA><-.HPJ%WN?'VT
M9VLH>7YCE.URX)Y.2ZC)E\U0T9",&S<H&#=,B72(!L.J^UN<A7\>F+NE4Z)F
MO13(Y,"?F?Y2B3SSG$VTF531<&GK8I,JMVB74*Y<9^=\B0!U1%^[->22XU[E
M?$J?.X].UL5[<4!P8QBE1.EDBMS%/2*L)@$GEE<3"9MQVV,4!W`0WU9/B[;O
M6/#JZL`34VP'1_TEI<\R3$!\,:[P.>K:].25O;L_]5*D>=466^N=,7IB/'W(
M$5$^3TLJ<IBD<4JG&2,;Z)P3;O$C]'CX`4X;#^CKG)[2R%)XIO*(.%5#32YY
M)4#**Y\2P1FE9.HL-^8PZEP!726XI8S(F;J,V/;6ZP?Y"OQE/K]/_9+E']75
ML?9Z<0OA+:TI,R@U`/,?$NF781$L</5`Y2I0-8W@/3O%G[,13OK0$._0Y<<>
MYY1,_NR1X[*Q35<P[E%]%9(MCIZW('2&WEMY5`X^(^*FNG/LU/(5E2O8'X1-
MPQ$<RF4`'M2>R)(H#\V1MQ?8A87U6JSPXXVY<4OU1?B!'(F/[89EN'7[D?51
MW"HNP+OU=/O"+5(([;;AII>TU3/>L;562_LYIW43^,%A4NQ0,8Z\'$D[)&)7
M.JNPGP:((-$$&B"#1!%;SWL8.2@.YSR?;R?J?,DINK3[3U0E$WNR;IT*]C_)
M$J:8>E].</+`=Q`OM$?;KH;P;?;?X;6Q34I)0M!E\)+B@>N>N%NE,V$PCS$'
M#[E%R!KKVW82P-DC*58C912#D)RG5]67CV<NDBFY4CG"Z1P\IV5NL4_2(;])
M@'3NNV;,LV&H327FNIJ:I4G$$N*PDIG*8').,BG6T&2B`8VM^3([@OXG>=O_
M`-*=?^LTE_6/D+];T/XP1YW[/PA&UL#=M[GI`YXP7.S/$G-T9#0>:L334Q).
MZ:Y2:1L3$Y!KLA)2#M45-DFK%DW454-^M(01TEWSB%D9^QUK#-UHE/+HWTI`
M<$RI32P`.<D@"/*WV<!&(:CYHLG=<[(1(-$$(,[HWYN?FO\`W;<K?<K(:?/#
M/]X-F_S%C^>(RL?AD_*$5X'!C^VUP\_O18$_G1J^K^9V_P!&7?\`RRJ^A7"T
M[^"5\D^:+3+7,J$"#1!!H@@T014S9Q_YMYN_E6RQ]W%BUU-LO^%47Z*Q]&B'
M"CT1T#S1:$<-O[(7%7^[=@W^;&KZYJ9O_P!673_,:GZ9<(+OX57RCYX4CINQ
MX@T00:((\Z7AXFP14C!SL8PF8679.(Z5B91H@_C9*/>)&0=,GS)TFJW=-7*)
MQ(=,Y3%,41`0VUD:>=8=2^PI2'D$%*DD@@C2""-((V$0:M(B.9S%^KA<<\PO
M9>Y\8K<\XZW&06</E:>Y9K6?$SYVL;K%-E&"NE-TY$ZIA,8&:KEN4-BIMB!X
MZL'E'VA<P6E"*/,K0N%(D`;P'`^`.4RPN?;`'E48W6ZU:="^\/+$4SF?V[>4
M?!"P-(S.U((2KS;M=G5LEU9=2<Q_9E40,?TS>7*@D>+EC-P!06+U-!R!!W`#
M``CJT&3^(&6<[L%VQO?VE`!6RL874<Y3M3/1B22(4&GFW1-!T\FV'+.QGW-L
MA\?<[T7BSDNT2%AX]9@G6]1KK&<?'<EQ7>I=0$X"2K[IV<ZC&N33_9F[8E,"
M`*+D53*!BB!HZXU\-Z"_61_,]N:2W?Z1!<64B6^;3Z06!K6D=Y*M<@03*,%6
MP%H+B?3'EB=\WDHYVZ?,6C]DZ>Q9T$Y-FW=(+.HY1RD#ALF^;IJ&5:'<(#UD
M!0"B<GB&X>.J0*;<0E*U)4$*G(D&1EH,CMD=<H1DN(4HH2H%:=8!TB>J8V3Y
MX[NO$>X88^L8L,6..W58']V2AOCN.R-CT,.N79$!G4[,[LC!*RMX-0VSD$7-
M((_%Z4H^6*293'`3%3U.'L_+N:>(#:*,K\"JG=WX$\.`(.`JV:',.';,F6@F
M(AXV(MZLE+75X?&)?;W)/I8BH8@G;I;Q8N;JB(5VG&,_(=R'AVA6A5+)IYCB
M7ASHIG5,2(81LJ\L)C`F8HE1&`1<@<PCTE*(B/AX:M=Q26PWP\NYJ);OPBA]
ML2D(_E2BMO#M#R\\6P,?A/%`_:@$J_DSBS<USAB^$&B"&(OK&_YLJW?RQX4^
MZ]/4W>SY^\=K]#J/HXB3C9_H1W])8_GQ&$[`_P"=4X\?[O9N_F8NVK)<=/W8
MW#^LIO\`V&X@/@_^\*B^0_\`0+BQ8US_`(NO!H@CC6`125``$1%,X``!N(B)
M1V``#Q$1U]&N/AU&*F7,0"EFG+H*@9,R68<C@J50!(9,4[]-^8"A3`!B&()1
MW`?$-M=2K1IL])+3.D:^B3'.NYZ+I4SV5+OTBHM5<-2+"7Q!BJ5BW:#^-D\;
MT=_'OFJA5FSQD\K,6X:NFZI!$BB*Z"A3%,'@)1WUS%N[:VKM5-.@I<34.`@Z
MP0L@@\X,=![8M#MMIW&R"VIAL@C404@@B-DZ3HWH-$$&B"&N^\_D8,9]M+E-
M*IN0:OK!26M&BU1.4F[^Y3D7!@F'4(=8J-72H`4/$=]27P@M_K+B+;&B)H;>
M+BNAM)5YP(8'%"M\#D6X.`R6MH-CI6H)\Q,0U.Q+C;[XG<XX^@HAYT=0D;QD
M5^/2)O3C6*;+^YEO`IBATV%VS+N/2`=7@.^P#;KC;<?5_#>OD9./EMH<^-Q.
M+^2%163A)0^-SY13$T,AQP\V%!PG[HB)TW<%XZ->5G#?/V$#MDG$O::#+/*B
M8Z:9U&]VKB86&IJ-U#_^S*+S4:D@90H@8J2Q_LB`TIR'F!65\W4%Z!(::?2'
M.=M?<7/E[I)ER@1;/.=D3F'+%9:I3=<9)1S+3WD2Y.\`)\A,5UG`KEE9.#G)
MVIYUC6KQP:`B;G5K+"(@!57["Q5Z1B#-E6C@4T5SQLYZ9R5-8.DJC<!VZ@#5
M_L\96I\Z9;=LCA`#BVUH5R%"PJ<QRIF)C88I5E#,3^4[\W=T`G`E:%)Y0I)&
MH\BI&1VB.SP:PQ-<QN<V$,;3H.9@V2\O-+1D9T*BAU3UEA*+72_OE7!^LP&-
M%,W)2&/])0Y"^TP!KSG2\,Y2R56W%B2!34A0T/CE.[:$OE$3Y@3'K*=K=S-F
MRDH79J+]2%N'XH.-PSZ`?)%G'<:;%6R@6G'JS=!O"6:GSE-5:I(D!LA%3,*Z
MA%&Z;<H%3!!-HY$H$``+TAM[-<WZ2L=I:]JO!)>;>2Y/:5)4%3GRS$7QJ:5N
MHHW*(@!IQI2);)*24RET&*K*@RLM@WDA3I8H#&3&)LY0BJ@"<2BQ5J-\00=!
MUHG*)100:'#<I@]GMVUTXKFFKUEYYH]YJJHE=>\:,O/'/FC<=M-[:<'==IJM
M/5@<T^:+6^,D6DQ&Q\LP4\UC*,6DBS5\/MK1ZW3<MU/`1#YZ*H#[1]NN7[C:
MFG%-+T+2H@](,C'0QM:76TN(TH4`1T'2(91[IU0699`QO>$T>EG.UF0KRZH%
M'8\C"/\`UA0.</`!]#)$`H#XCL.VJ)^U?9EL9BME]2/F:BE6R3\=I>+7\E8T
M<T0?Q6HRBXTU<!W'&B@GXR3/S*A0/:]O:,OBBW4!94GKZ=:U)-ND8X>::)LC
M9-4@II^T46[YDJ`F#]<IMJ1/96O[=9E*LR\LCQ%%5EP">G=O)!$AR!25:>54
M.'A97I>M+UO4?G&7L0^2L>8$'MA"_P!8WXGRV:N*-6SS4(H\G:.-,_(R\X@U
M1,J]6QC<$X]A;%R%3*)E20,A&L7QP'?H;IK"4-Q'723V>\TM6;-#MCJU8::X
MMA*2=0>;F4#[8%2>DIB7J)S"Y@.I7GB+5VL>=;O@+RIKV4),KU_BNWL?@7,4
M,PZE5W%/D'*:[:?8MBF`KJ5J,F4CU`@^*B7G)`(>;N%FN)V2$9ZRPY;&\*;H
MTK>TZCJ#@$BDG8EQ/=/(9'9"@^UOF\/OMD60V/<ATG+%)K61L<6:)N-'N$4U
MFZW9(1T1W&RL:\(!T5T%2^)3!XE43.!5$E"F(<I3%$`YY5]!6VNL<M]Q;6S6
MLJ*5H4)%)&P_8.HC2-$(BDE)PJT$1F6M./D?)C%(4QSF*0A"B8YS"!2E*4-S
M&,8=@*4H!N(C[-`!)D-<$:/P_P`E\"9^D;W$8:RM2\BRF,[$ZJMX85B::R+N
MOS+0_EJ).D$C]9V:B@"5)TF!VRIBF`BAA*(`MW;+E]L+;#MXI7J=NI;"VRM)
M`4D\AY>4'2-HCTI"T2Q`B<;RTB1YB&/]9JXMRL)E+$G+N!BU%*S=*ZAB?(+Y
MND)DX^W5U5Z_J+Z1.&_EA.U]T=FD8=B]4<4OTCAO<#V;\S-/6RKRH^K^TLN%
M]H':VN0<`^2H!1^7/9"G0N326CK&D0G3L!]PVJ\5<PVGC]F*=:UW$6>W\8]A
M+1*.4VT/3,I,421C!66=+B5%A"VR,$C59<QBIH.4$#'V*8YBN#CMD"JS1:&K
M]:$%R[4*5!2$B:G&3I.$#6I![P&L@J`TR$>ZQDN)QI](>:)WZ*R3A))=!5-=
M!=,BR*R)RJ)+)*%`Z:J2A!,11-0A@$I@$0$!W#5(""DE*A)0A)CDU\@@T00:
M((09W1OS<_-?^[;E;[E9#3YX9_O!LW^8L?SQ&5C\,GY0BNIX<S\-5>7?%>T6
M*1:P]?KG(W"DY.2SU0$6<9$161ZX]D9!VJ;P2;,VB)U#F'P`I1'70'-S#U5E
M.Z4U.DK?<M]0E*1K*E-+``YR=$+3@FVH#7A/FBU%161<(I.&ZJ:Z"Z9%D%T3
ME51615*!TU4E""8BB:A#`)3`(@(#N&N8Q!22E0DH:Q"!')KY!!H@@T014T9N
M*)\NYL(4-S&RQE<I0^R)KS8@`/\`PCKJ;9M%IHC_`.*Q]&B'"GT1T#S19P\"
M;?7+SPHXIV"K2K28B3<?\3Q(NV:R2Z9)*O4B%@9EDH9(YRD<1\M&K(J$$>HI
MR"`@`ZYN9YI*BBSE=&*I)0[X]]4CHT+<4I)Z"D@CF,(3P(=4#\(PK;35C'!H
M@@T01TPD8\T@>)*_9FE$VA'ZD:#I`9`C%14R";T[,#^H*T47(8A5!+T"<!`!
MW#7O=N;O>X3NB93D93URGJGS01W->((;7[OJ&+U^W'RG^^P6*&$1QR\7KAY,
M$!63R&FY;?>_/#F5`5B2QK0+<I!1^V>290!^UB?4B\)E7-/$*V>JL6^-0`N4
M_P`%([W%LPX)Z]$Y;91GI\6^3AUSBNIX^LIJ2SO@UA``H-A>9>QBA#>20ZBI
M)92Z0@,E"D3W./DN>DX[>(`41UT"ORV6['6N/_\`;BD>*OD[M4_)"RL@(,]4
MC"_>X'RAY5X[[DG)+,U<L&:..-LFL@K1=<(1:Q49Z^I=48L*]5BJL5_(CYA@
M]B(M)R=(Q7")CK&ZM]QTP<AY:RQ7\/+=:*ANCN%*AC$O0AT!Q9*UZ1,I(4HB
M>@Z(H#G*_P"8:+/%==&5U5#4K>DGTFR4(`2C1J4"D`RTC3&55WOY=SVOQ1(Q
M7.5?L9B(^0$I9,94AW*[`!`*J=Q'1<4W47*!/I&2$1W$3;B.^M:HX&<-GW=X
M*)QO3/"AYP)["5&77&PSQ@SZRWNS5H69:U--D^0#S0A#/?*;E1SAOT&^S1D.
M[9IN)%%(^G5AHQ*JUC!?J$!1E4J35V#:/9J.C%("AD&HK*@4!4.;;?3WL>6<
MLY+H5HL].S1TFMQ9.DRVK<623+9,R&P0T;QF#,&;*Q"[H\[55,Y(0!H$]B$)
M``GMD)G:8E>]A[M)Y`X[3+GF!R;KJE4R9*P#N!Q)C*4(F:<I<%-IIA-6ZUHE
M,<L999IF`-6S(=UV;4RHJ]"BG06KO&_BI07]D93RXX';<AP*?>3Z+BD^BV@^
M^0D]XJU*5*4P)Q8?A%PYK+*X<RWY&[KU(*66CZ2$J]):^12AH"=8$YR)B43J
MM43[!H@AB+ZQO^;*MW\L>%/NO3U-WL^?O':_0ZCZ.(DXV?Z$=_26/Y\1@^P.
M(?E5./'B'_V]F[Y?_P#&+MJR7'0'ZL+A_64W_L-Q`?![]X5%\A_Z!<6+.N?\
M77@T00:((K=^\)P6R)PYY:9,G'M>D5,*9DNUCR!BZ]IHK.(1T%JD#SLW4Y&1
M!,$6=E@9B353.@KY9EDC$42`Q#;ZZ%\)LZT&;LK4S*'$^N:1E#3S6I0P#"E8
M&U"DI!F)R,P=,4@XEY3K<LYC?=4A7JNJ=4XTYK2<9Q*03L4DDB1UB1&B-`XA
M[EO/'`M&B\:8EY0Y)J-#@@,G!UDCF&FHZ$;G,)A91'Q%$R[B-CBF$1*V1.1`
M@B(E(`B.EV[<.LD7RM5<;K;*=VN7Z2Y*25'E5@4D$\YT\\(]LSUFZSTB:&W5
M[[=&CT4S2H)'(G$"0.8:.:-G?ED>YS^.'D?_`%;1O^$])OU1\-_U13]KGW\*
M'UG9\_63W8W]Y"R^W9W3NX)EOG9Q2QCD?E%>[90KUF*`KUMK,@PIZ;&<AG32
M24<1[I1E6VKLB*IT2B(IJ$-X>`Z:.?\`AED.U9)NERM]L8:KF*12T+!7-*@1
M(B:R.T0Y\E<0<Y7+-MOH*ZO=<HWJE*5I(1)22#,&20?+$^W5%XN!$<?ZS3D0
M*WP?Q]C\BPE5R?G6M(JH%/TBHPI<1,6E510NX=2*3]LU`0\?GG(/R;A8/V<;
M?XC.E17D:*:B7VN*2CS$]4XA+CO6[C*C-&-=15I[$!2_.!#7GU7W'9)OE'R"
MR<JCU%H.&(BM-5S%`2$=Y`MA'"I$S"/@L#2F&W$`$0(80$0`WC)7M*7`LY9H
M+:#I?K%+(YFD2[)N0P>`=$'<P5M>1^!I4I'2XOW$1-[]NJ91:N*T3N]<<#<8
M.X#GNF,F`L*E<K#]]FBE*4P-QKV0^N;<-FYQ`$SA&6!1Z@)2;%3*0I=@VVUT
M7X49A_:7(E#6+5BJF6]P[RXVNZ">E.$\^N*+<2;'ZASE64J!*F=7OF^3"YWB
M!T*Q#FAX#ZL!QT"<R9GOE++L1,UH]?C\1TMTJ0P%]\VM1*=MKEJ82B146\5%
MM&YQ`0,GYPA[##J)O:3S!N+=0Y9:5WGG"^X/BH[K8/2I2CSRB2N`EDWM?69@
M='=:0&4'XR^\LCJ`'7$SO508L_%8!W0\<&Q=W`^8-+\L6Z0YJN%E8I@`IE3C
M[\L6[QI4`V)LBFSL1`((>P`]OAKI-PUN'K/(=IK-9\&V@]+7S9GSS09Q0G/U
M#X#.5SI92'BEJ'0Y\X/(J+$S@;D<N7.%W%S(Q5`5-:<'8Z>K'`2B/JD*VP8/
M"GZ2D`%2.FARG#8!`X"`^.J!9XMYM6<+G;Y2W5:Z.HK)'D,73RA7"Y96M]</
M^)2-GKP@'RB.ASCQ`XR]@6?;Q+47=FIBQ+G`(IANLY4BT%R2;!+8-S&>Q*ZP
M%+N`&5*3[`:KAQWR:YG'A_4-T:,=THE"I:`UJ+8(6@?*;*I#:H)C0SW9E7BP
M.)9$ZI@[Q`VG"#B'6DGKE#*'$?.7WA<QPUED%%"U.;)\-7-(H&^UPSU=,Q)/
MR_`QEH1X0J_3[1(!R^T=4>X/Y\^K_.;%TJ"1:'QN:D<C:B)+ERM*DKHQ#;$'
MY0OW[/WE%4X3X-P8'/DD^ETI.GHG$E=RW@;C77#1TC'V&L6F&6;.6ZI4GT5-
MP4VR,BNBJ0>M!W'R4>Y$I@'<JB9]O8.NHU'6)6EJX4#DTD)<;<0>A2%I(ZB"
M.F+0-N(<0EUH@H4`01J(.D$1`E[M79MR/P_N=ES-@>LS5YXLSSYW-#[F;+RD
MUA=9\Y.JM7;*R;@J]4J3514"L)0"F3(ETI.!(<H&/>SA7Q=M^;:-NSWQQ#&9
MFTA/>(2FHD/303HWA]\C7/2F8U+-/4I<`2O0YYX0'PX[D'++@V^4'!.1SDID
MB[*^F,8VQO\`$V.IA8P`"CHD,NLFM#2"R?@+J.7:JGV#K%0`Z=/O-W#S*V=4
M#UY3?VQ(DEY!P.I')B'I#F6%#DE&9QEMWTQIY=L/7Q/UH_-J48DE-\4\8/)@
MB9BJNXV^VAE'KJ`39-4&CF+=.$`.?Q.4%#[?(.H;=]F>S%TEFZ5*69ZBT@D=
M8(![(U?`)V*,-T\P>][S=Y>5Z4H;JPPF%,932!VLS2\2D?1[J=9*@)5H^>N<
M@LM9'L:L0>D[=`[1%4NX*%.4=M2#E+@QDO*CZ:Y+:ZRY(,TN/R(2=A2V.X#R
M$XB-DHSM4K39GK5SQQ=GKB9S5S5R-J>2^,$_9<+52D2[;X[ST9JN2IMH,BY%
M9:H(LG*9HZ_2DVS*H@6,$BS<AC]:YDBE$VCBUFK)UGR\[;LRMMUE4\@[JFGW
MRKWKDQI:2DZ<>@[$S,%2XTA!#FDG9%BPB50B21%5175(F0JBPD*F*RA2@!U1
M3(`$(*A@WV#P#?PUS])!)($A/5"+&H<_8'QIR9Q%=\(Y=@$;'1+Y#KQ,LS,/
ME/&:H[*,)F'>``J1TW#/2$<-5R>*:R8;@8HF**M8KY<LMW9F]6EPMUS"PI)V
M'E2H;4J$PH;0>73'I"U(4%)UB*\KN']J7D1P&MTP[EH&4R+@!T_5"G9I@8Y5
MY%#&K"<[.-OS5JFH:H65ND42+`L`,W`D$Z"IBCTEOUD#BAE_/5(A#3B:>^A/
MSE.HR5/:6B?PB#LEWAJ4.599J$.C09+Y(]OB#WG></#R`C:-5KO%Y/QA$IHM
MXF@979N+"T@F20F$K&LV-NY:V2%9;&V*AYZ[9(H;)I$UAS9P?R7FU]5;5,JI
MKFHS4ZP0@J/*M!!0H\\@3M)CXY3-.:2)*Y1#ADS]:"Y3/8A5G"\;\&P4N=$2
M)S2MBN\TB@KY8E!<L0J#`A]E!`W09<0V#;?Y=,!GV:LLH="WKC6K:GZ.!M,^
M;%I\T810-[5&%(]I/OC9=S5R@EL,<S+=6EHW-"S1#$,Y'0D94X&E7=J14J%'
M*1N453Q=P0-TM57CAPN603(GYFRP`#>XJ\%K39\M(O&4&G`Y1@E])4I:G&SK
M<T^^;VA(`P3,M$>*FE2AO$WLUQ+?U52$Z-49VQ-"9XPOE3"]D.9."RE0;319
M-8H=1F[:RP[N+%R!0$.L6QG`*=/AU=.VE2R75ZQWBEO%/I?I7T.CG*%!4NN4
MH](44*"AK!BL`Y/\7LP\0\MV7#&;*K(5ZP03]VA%RCAJL6!ND&FNHG'V>K29
MTRM):)E&Q2J@*1A,D8PD.!3!MKI5EK,MIS9:F[Q9G4N4ZT@E(/>;5M0L:TJ2
M=&G7K&B%UMQ+B0I.J/5J_-/F#2(-A6:;RJY"U6N13=)I%P,!E^\Q<3'-42`F
MBV9,&DTFW;()$`"E*4H`4`V#6*IR=E.L>54U=KH':A9FI2F&U*)Y22F9,!:;
M)F4B?1&0?U_^=/XY?)W\-^0OX>U@_83)7ZGMO]V:^]CYNFO@I[!"]NUOS/Y>
MY`[AW$FEWKE+R`N=/L>4C1]@JMGRU=9ROSC`*C:'(,I:(D)A=D_:^H;IJ>6J
M0Q>LA1VW`-,;B9D_*E!D"ZUE%;*!FK;I9I6AAM*DG>($TJ"009$B8C#4-MAE
M1"1.7)%A7J@T(\5OG=VX)Y`X9<K<C2"]>DCX2RQ<)R]8JO239=:"70L[Y69D
MZC(20$\AI9J])O54E$%1(==+H63`2'#70SA1G>@SAE>G0EQ/KFE:2T^W,8@4
M#"'`-90L`$$:C,'2(6Z9T.MCX0T&$*XTY+<B<+QKB&Q!GG+^+H=VN=RZBJ!D
M6TU2-7<J]/FKJ,8:3:-C+*=`=1NG<=O'3WN.7,OWAT/7:AI*IX"04ZTA9`Y)
MJ23&52$*TJ`)Z(V9_7_YT_CE\G?PWY"_A[2=^PF2OU/;?[LU]['G=-?!3V"/
MDW/_`)T[?VR^3OM+_P#V_(7RF#_Z]H_83)7ZGMO]V:^]@W37P4]@BT)K2JJ]
M<@%UU#K++0L4JLJH83J*JJ,4#J**',(F.<YQ$1$?$1'7-.H`%0X!H`6KSF$(
MZX@7]\;D-GBL=SVW6^H3.4\-GQI4J;C[&MNBG-BI:\O%L8T)R;?P$NV,R;RT
M6^LDV\$!2.J11+8#A\FKQ\%K!8ZGAJU25:*6L%2ZXZ\VH(<"23A2%),RE00E
M.L"1U0K4J$%@`R,]<:<H7?H[FM%C"19\VP5Y321%!%Y?\=U.;DTR;$*0PR$<
MRA5W*R8$\%%Q5.(B(F$WR*]=P.X;UKN]%$M@DSDTZM(["5`#F$AR1Z-(P=DN
MN$<\I>?/+7FFZB6_(++LY=8J+>@O7J1&LF%?J+"15`4R.&-6K[1HV?RI@.)"
M+N`<N@*;I*?;PT[LLY%RKDY*U6&D0RZH24X25.$<A6LDA/*!).V496VFVO0$
MH?<[%O:2R>ZRS4^9O)*E2-'I%#+[]PQ2K2R48V.Y6QRW,E'721A'0)NXFMP#
M=P9=F+DA5'CHQ#E)Y9.H80XV<5;:FU.Y/RZ\E^M?[M0X@S0V@'2V%#0I:B)*
MEH2F8G,QJ5=0G"6D&9.OW(EWY'P[B?,$4>#RKC:C9%B%$Q2%A<ZO#6-`J9MQ
M$J02C-R9$!W'Z`E]NJHV^[W2TN[ZUU#U.[RMK4@_R2(;U=;+=<V]U<&&GV^1
M:$J\X,(ID^T1VU9613E'/#K#B+A-8ZXHQT(YBH]4ZA@.;SHR-?-8]1/J#P(*
M?2`>P-/%OBMQ%:;W2;O5E,MJ@H]1()\L-9SAMD5QS>*ME,%3V)('8"!Y(4IA
M[B+Q>X^F\W"F`<3XS=?-$9"I4F#C)41*42@8TLFT&3,<2F'J,*NYM_'?3=N^
M:\RW[1>:ZJJ4\BW%%/W,Y>2%RV9;L%FTVJCIF%<J$)![93\L**TWX6X-$$&B
M"-9Y;PQB?/5-<8\S1CRI90HSJ0CI5S4[M"LY^"7DHA<'48^4CGZ:K<[E@X#K
M2.(;D-XAI1M5WNECJQ7V>H=IJT)*0MM12H!0D1,:9$:XT;C;+==Z8T=T9;?I
M"02A:0I,QJ,CHT1IC%W`[ACA*[Q.2L1<8L*XXO\`!)22$-<*?0H*#L$8C,1S
MF)E4F4FR:).6Y)",>*H*@4P=:2ABCX#I8N>=\WWFB5;KK<JRHH5D%3;CJE).
M$A29@F1D0".<0E6_*.5[55IKK;04K%8@'"M#:4J&($&1`GI!(/-"L]-:''!H
M@@T01A][Q[1,H5M]3LCTZLWNJR9!(_KUMA(Z?AW0"4Q`,JPDV[EN*A2G$"G`
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M-&'/&C<U\9N/G)!I`L<^8;QYEYG5G+UY7&M_K,;94(5U(I(H/G$:G(HK%:K.
MT6Y"J&*`"8I0`?9I:LV8[]EY2UV.KJ*1;H`66EE!4!J!EKE,RA)NMBLU\2A%
MXI6*E#9)2'$!6$G61/5.4<.$^+W'7C<2?3P'A7&^("6H[%2R!C^JQ5:]^'C2
MK$CS28QK=$7?HRN5`3Z]^CK';VCKU><RY@S"6S?*RHJRU/!O5J7AGKE,Z)R$
MX^6JP62QA8L]*Q3!R6+=H"<4M4Y:Y3T1OC2'"O":\S\..*G(JPQEMSMQ\Q-E
MJSPT0$!%3U\I<-8I5A"@[7?A%MGD@V6629`\<J*@F`]('.(_+IQ6?-V9\OTZ
MJ6R5]52TRUXE):<4A)5("9`.N0`G"%=,L9>O;R:F[T5-4U"4X0IQ"5$)G.0)
M&J9)C/L.X+PWQ\JJU&P?C*EXII[B7>3R];HL`PKL.M-/TFR#V4591R***CYT
MBS2*=00$QBIE#Y-:-WO=WOU4*V]5+U55A`2%N**U!(F0F9V"9T<\;ELM-LLU
M.:2TL-4],5%6%M(2G$93,AM,A&UM)<*,)(R9P)X69FNDOD;*_%["60KY/^D"
M:MUMH$#-3\IZ!HBQ9>NDGC11RX]*S0(D3J,/20H`'@&G5;L\YPM%&BWVNY5E
M/0HGA0AU24IF9F0!D)DS,-ROR?E:Z52JVXV^D>K%RQ+6VE2C(2$R1,R`E"@\
M>8ZHF):;!8\QG4H&BT6KM!85VIUB.;Q,#"LA547%K&QS4A&[1#SE3&Z2``;F
M'2#7W"NNM6NON3JWZUTS6M9*E*/*2=),+-%0TENI445`VAFD;$DH2))2.0`:
M!&:"`"`@(;@/@(#[!#[`ZTXVHCZ\[>+;O$%Q=Y&J4<(XQN4B=8Z;5,YDJE87
M@BJYBW(``E1CI)<3JM##\T!$R7M*7?G=Q\X4O9-O2\R6AO\`_P`M6NDR2#*G
M>5I4VKD0LS4V=6M.P3KQGW*B[-6FY4:?_EOJGH_X:SK2>0*.E/9&;\+.;R>,
M4&.*<M/'2]%%8J%8M)Q.Y5I_G&'>.DB`!G"]>,J?<AR]1F@B/@*?T5S@CQT3
ME9MO*6;UK58,4F'SWC3S]XO:69ZB)EO3H*=6]DC/0M:4VF\*)H)R0YKW?Q5;
M2CD^#T:GOVSJ%LL0FY:+QL]!3++=-5$[:2BY./>);#L8HK-7;5RB?80^<4Q1
MV'PU>^CK&*IENNH'4N,+`4A:%`@C6%)4DRYP08G9IUMYM+S*@II0F"#,$;""
M(9VY/]A_@-R2E92UL*7,X,O$LJ9T\GL./V\!$/GASG44<R-*>M']7.=<YQ,J
M9J@S54'Q,<=3-EKC?GK+K2:5QY%;1($@FH!4H#D#@(7T8BH#8(W$5;R!*<QS
MPW"Y^JQXY.Y5.TYEW]LT,?=%NMB"LNEDD_#YBCD+DW!8V^_S@3+^EJ0D^TW<
M`D!=G8*N7?K'DW9\\9_'GX([85Y@+ZN5P6Q1),)[)CW(?(.68J)+%CKK*MZ_
M25EDC%.51Q5JPDU<O2"8/G(N7Z[<Y1V,F8--2^^T)G:Z-J8MJ:>@:5M;25.=
M2US`Z0D'GC&NM=5H3(0^S3J74,>5J(IM#K$#3JG`M$V,+6ZU%,H6%BVB0;$0
M91T>B@U;D^4>DH"81$1W$1'4(UE95W"I765SJWJIPS4M:BI2CRDF9,:A))F=
M<(JY5<XZCA9K(T^BKL;=E%1)1N*"*A7,)45CE$H.IU=(3)KOT-^HC(@B<3`'
MFB0OMKGQ9X[V?)#3EFL"FZS-9!$@9M4Y/OG2-!6-8:&F?IX1KCW-F>Z.R(51
MT!2]=92EK2WSK.TC8D=<A'UQ+YLUG-D='TZ]O&-<RPW1!`Z*HILXFX>20/V_
M!G.)447ZP`(JL=^LI@$4NHG@7[PAXY6O/%,W9;^MNFS<D2(,DMU$O?M;`LZU
M-:P=*9C490SQ2WQM-%<%):NX$N1+DMJ>0G:GLF(75*Q47.QSR'FXUA,1,B@=
MK(1<HS;R$<^:JALHW>,G::K9R@H'@8ARF*/RAJPS3KK#@>94I#J3,*22"#R@
MC2#$@@D:1KAGG/G8;[=.=9!].-L8S6&;#(*'7=2>%;":ILEG!S"<RAJM(,YR
MI(^8H(B?R&*!C[CN;?80EJQ<<>(-D0&55**RG2)!-0C&0/E@I<[5&-E%6\C1
M.8YX1HA]6#XF%DP7<9WSRM$>:)AC4CTU!X*(^Q()08)8H'#_`"_3^/V-.]7M
M*9I+>%-#0AV6OYPB?R<7V8R^.<Y!#BG&CLT<`.+<U$VVG8="ZWN#7;/8F\98
MEE[U-QD@T,!V\E%LGB;:M1,BDH'45=JP15*/L-[-,#,?%_/F9F5TE75[FA6"
M%-L)#22#K"B)K4.8J(C"Y5/."1,AS0Z.LN@V3%9PLD@D42@9590B291.8"%`
M3G$I0$QC``>/B(ZBY;C;2<;B@E`VDR':8UE*2D340!SQRZ]Q]C5&6L$X8SS!
MIUK-.+*'E*!14%5",O57B+(V;*&VZCM0DVK@S4Q]@ZA3$O5L&^^E2U7N\6-_
MQ-GJGZ9\ZRVM2">F1$^N/25J09I)!A,OY+OMU?B5\<?P6UC]XZ<GUE\0/US<
M/QR_=CWOWOA*[8/R7?;J_$KXX_@MK'[QT?67Q`_7-P_'+]V#?O?"5VQEM#[?
M'![%URKV0\=<4\%TJ\U)_P"]*Q;*WCROQ4[!2/IUVGK8N1:M$W#1SZ5THGUD
M$!Z#B'L'6I79]SI<Z1R@N%TK7J)U.%:%NJ4E0F#)0)D1,`]4?"\ZH2*B1TPL
M332C'&(7G']%R=7'U0R+3ZU>:M)D%-_7K9"Q\]$.BF(8FZK"2;N6XG`AQ`#=
M/47?P$-;=%7UMMJ$U=O><8JDZEH44J'6"#'T**3-)D81[^2[[=7XE?''\%M8
M_>.G;]9?$#]<W#\<OW8R;][X2NV#\EWVZOQ*^./X+:Q^\='UE\0/US</QR_=
M@W[WPE=L'Y+OMT_B5\</P6UC]XZ/K+X@?KFX_CE^[!OWOA*[878@@BV11;-T
MR(H-TDT$$4R@5-)%(@)IID*'@4A"%``#Y`#3(4HJ)4HS43,QBC!<AXIQEEN&
M4KN4<?4W(4&J0Z9HNY5N)L3,"J=(G!-&5:.BHB?I#<2=(CMK>H+I<K4\*BV/
MO4[X]\VM2#_)(CTE2DZ4DB$#6/LU]LZS.Q>/.)>.XY45RN!3K:MAK#03EW^8
M#*!FH]H5`V_BF4@)C]C3ZI^+W$>F1@1=:A0E+OX%GM4DF?/.<914OCWQC=V'
M^WIPDP+((S.*>,>(JK.(&ZT9\M38RT\D<#&,4R4S-EDI%(R8F^:)%"]/R;:1
M;MG[.=];+-TN56ZP=:<92G[E,AY(\J>=7Z2C*%E::$8H-$$&B"#1!!H@@T00
M:((-$$&B"#1!!H@@T00:((-$$&B"#1!!H@@T00:((-$$&B"#1!!H@@T00:((
M-$$>#9ZQ7[G`2E7M,2SG("::*L9.+?I`LV=-E0V,4Q1V,0Y1V,0Y1`Y#`!BB
M`@`ZT+I:[?>[>[:KJRA^WOH*5H6)I4D_[3!$B#I!!C7JJ6GK:==+5H2Y3K3)
M23J(/^VO6-8ABSDSV_KKC5S(6S$S9_>:$8ZSI6&03%U:ZRD)A4,B=JD7KFXU
MN0=BJH@*Y2E^>0?I#0GBA[/-\RPZY=\HI<K\O3*BV!BJ&!KEA&EU`V*3-0`[
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MT]T7#\<BL%3IMVL[L"F]/ZQ*/K[`Q@WZ?/7<.7;M,H_YJ!QTBW7VJLFTR"+1
M15U4]+1B"&4=9)4H=2#&C5\5+.V#X1A]U>R<D#K))/D,(0S+W`LW93:.X2&6
M98TK+LIT5V=75<'FW;<_4`HO+&XZ'10.0PE,#8C<I@^34!9U]H?/6:V5T-$I
MNUVM<P4L$[U23L4\>]I&@X`@&&#>N(=\NJ"RR4TM*=803B(YUG3]R$QKS`O$
MG+>?WZ+R*C5J]3E%C&D+U84'"4><-^I;W6DITNIUZ<1_\W]KZAW.H'CIN</^
M$&<.(=0'J1HTUF*N_5/`A'/NQZ3JNC1/6H0G9?RA=\PN!;*2W13TNK!ESX=J
MCT:.4QXF<>,V6./LTH6RQ#IU7TW75"WN#3<*P;LI%-VZAW:1?-AI$``!%)?H
M,4WT3&]NM'/?"_-W#NN(NC*UVX*^;JF@HM*TZ#B&EM?Q52,]1,8+[E>[Y>?(
MJD$T\^ZZF>$\FGWIYC(\DXW-A_N%9PQFT;0\^HPR=7VQ$T4$;.JX2G6S=/I`
M$VUB:]3A82D+TE%TFXZ0_1T]<F^T7GO*[***X%NZ6Y(``?)#J0-B7DZ3HT#&
M%PM6;B+?K6@,U!354XU!<\8',L:3]L#"Y:QW1L0R"21;52[O6G(@7SS,TXZ?
M8E,/TO)5;N6CQ0I?\Y`@ZGBU>U7DZH2!=J&NI7=N$(=3U$*2H]:!#\I>*MG<
M`%6P^TKFDL=4B#Y(S93N6<;"D.8BEZ4.!1$J85-4HG$/84#&=@4N_P!D?#2X
MKVGN&0!*37E7)X<B?:J-X\3LL@3!?)_JS[L:>N7=,K2:2B..\9S$FZ\2IO[;
M(M8IB4=MP5!C&&D'C@@#[2BH@(_9#Y6;>O:NMB4EO+EK>==V+J%I;3TX48U$
M<TTGGA&K>*U*$D6ZE6I>PN*"1V)F3VB$&90Y+9=SB[`+E8SHPQ%07:U2!*I&
MU]L8A^HAS-4U#KOU4OUJCA14P;`(;#XZK_FKB?G#/;O_`-JI*:(&::=J:&4R
MU'""2HC85E1B/[KF>\7U?]M<DS.8;1H0.K6>DDPH7#',K+V/FC2'?O6UZKZ!
M2HH,K*==20:(E$I2ILYM$WK.DA"[%!;SBE`?8.I%R3QKSEEYE%'4+37VY(`"
M7B2M(Y$NCO:!J"L0$..RYTO%N0&7%"HIP!(+G,="AI[9PO6J<X:/,I(EG*K8
MH1R8H>:9J=G+,RB/M\M0JC1T8/TT@U8"T<=[#7(`KZ2I8=VX<+B>HS2K^3#_
M`*3/=`\`*AIQM7-)0^P?)&VF7)C&D@`>F/.F$0W`#Q!R;_8#<5=@WT\&.*&5
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M`&OSM4KS']6_B%_LKZXW,^[O]QAES>_[8A:Y?LWO%>JO&8)Z,>"7WW;&D?TO
M9\FF-"'&>5#[UWGH_'WQ_P"GZR^?\(?#OF='4/5T^^?DZ=O9X^W;Y-+]G_97
M>#]H/6&[GI\/N9__`-(4*+U5B'K'Q&'^CP?[T.E\</R<GKH[TO5\8=;?R/OT
M>JZ?6_\`NWJ/]D?V3;;J\.K;I\=6MX:?PU[]O=3]<S$O66+TOBXO[/KY=LI1
M*N6OJVQIP_\`>S$O$SU\T_F^V'>F/H?1M?=GI/=_D)^B]#Y/H_3=(>5Z7T_V
MCR.C;IZ/F[>S5QJ?<;A'A<'AL(PX)8<.S#+1+DEHB8F]W@&ZENY:):I<TM$H
MZLY[C]T2'Q)[J]Q>F4]Z>_/2>Z?1]/V[U_K_`-I^FZ?I>9\W;VZQ5_@/!N>L
M]SZOPG>;W#N\.W'C[LN6>B/#^XW*O$X/#R[V*6&6V<]$NF&8^0GY.+UDG[K]
M]?%'4KU_>;]5[I];N;?J]=_LKT_8\C[3[-OEU2?B-_#5OW?";_UK,S]78MWB
M^V^8^Y[O)$*YB^K7&O=8_%_^-/#/K^;[-$-I6CX`]0K\%?&?I>L/(^+/<7J?
M+W#?S?<WVKKVW]GAJL=U_9[>'U'XW<ST>(W6*7/N]$1C5^K\9\#O\&S>8)_R
M8Q-/R_,)YW7Y767S/*Z?,Z-PZNCK^;U]/LW\-](Z<.(8YX)Z9:Y<T:8E/3JA
M1>+/ZKWKFGWT_OQ^1YA?4^X_AWW;T^'5U>E_TUM_Y'CM^CJ2<J?57XA'[6>N
MMWHQ;K<X/Y/SG9#DM/[+8T^MO&X=N#!A\G>[(>GXZ?U+_=JOWF_@CUWH3^\_
M?^_Q9Z7ROVUZWXI_;WD>5^S>1]HV^EJ[O#;ZDO#']B_`^(W??WO_`'&&7>Q;
M_O2EZ6'N\L3=EO\`8G=GU+N-YA[V/\)+;/>:9<LM'+&CLQ_U$O>+STOF?$GF
MJ>=]ZGU/HO5>/[+T?[,=&_\`Z'YF_MTP\Z?4'XE>ZGZSF9^`GAQ<_P#P9?)T
M0A7K]@MXK#/Q.WP\Y3_F=D)<+\$^>?X3^*_3]7VGXB]S^;T;^'7[M^;OMJ)T
M^H]Y_P#(\7NIZ-]NYRY\$-/^PX_[)OL.S'A_W8V_4MNI+?V>&^WMV\-/6T^]
MA8I-8A85`^&=T?7^^>KP_8?2>5OOX[[?;MOTM3)E[U7)/B-_/FPR]V'K;_"S
M&\Q^27NPK&%]U>F)[L^ATA]/K\W;_/\`,\=2]0>$W/\`9/1Y]?7#M8W6'YK5
='M:WHSP:((-$$&B"#1!!H@@T00:((-$$&B"/_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
